

Dublin Declaration monitoring 2024	
Tab	2024 Indicators
<b>0</b>	<b>Country Info</b>
<a href="#">2</a>	<b>Size estimates for key populations</b>
<a href="#">3</a>	<b>HIV prevelance</b>
<a href="#">6</a>	<b>Laws</b>
<b>8</b>	<b>Prevention</b>
<a href="#">8.1</a>	HIV prevention policy and provision
<a href="#">8.2</a>	Sexuality education
<a href="#">8.3</a>	Coverage of HIV prevention programmes among men who have sex with men
<a href="#">8.4</a>	Coverage of HIV prevention programmes among people who inject drugs
<a href="#">8.5</a>	Coverage of HIV prevention programmes among migrants (persons born abroad)
<a href="#">8.6</a>	Coverage of HIV prevention programmes among sex workers
<a href="#">8.7</a>	Coverage of HIV prevention programmes among transgender people
<a href="#">8.8</a>	<b>Coverage of HIV prevention programmes in people in prisons and other closed settings</b>
<b>9</b>	<b>Condom Use</b>
<a href="#">9.1</a>	Condom use among men who have sex with men
<a href="#">9.2</a>	Condom use among people who inject drugs
<a href="#">9.3</a>	Condom use among migrants (persons born abroad)
<a href="#">9.4</a>	Condom use among sex workers
<a href="#">9.5</a>	Condom use among transgender people
<a href="#">10</a>	<b>Harm reduction policy for peple who inject drugs</b>
<a href="#">10.8</a>	<b>Needles and syringes distributed per person who injects drugs</b>
<a href="#">10.9</a>	Coverage of opioid substitution therapy
<b>11</b>	<b>PrEP</b>
<a href="#">11.1</a>	PrEP policy and provision
<a href="#">11.2</a>	<b>People who received pre-exposure prophylaxis</b>
<a href="#">11.3</a>	PrEP: Unit prices
<a href="#">13</a>	<b>HIV testing and policy provision</b>
<a href="#">14</a>	<b>HIV testing volume and positivity</b>
<b>15</b>	<b>Testing - Coverage among key populations (KPs)</b>
<a href="#">15.1</a>	HIV testing among men who have sex with men
<a href="#">15.2</a>	HIV testing among people who inject drugs
<a href="#">15.3</a>	HIV testing among migrants (persons born abroad)
<a href="#">15.4</a>	HIV testing among sex workers
<a href="#">15.5</a>	<b>HIV testing among people in prisons and other closed settings</b>
<a href="#">15.6</a>	HIV testing among transgender people
<a href="#">16</a>	<b>Linkage to Care</b>
<a href="#">18</a>	<b>Continuum of Care for all people living with HIV</b>
<a href="#">19</a>	<b>Continuum of Care for men who have sex with men</b>
<a href="#">20</a>	<b>Continuum of Care for people who inject drugs</b>
<a href="#">21</a>	<b>Continuum of Care for migrants (persons born abroad)</b>
<a href="#">22</a>	<b>Continuum of Care for sex workers</b>
<a href="#">23</a>	<b>Continuum of Care for people in prisons and other closed settings</b>

COUNTRY INFO

DDM 2024	Question	Response
ID.Region	ECDC Region:	EU/EEA
		Non-EU
ID.Name	Please enter your unique access code:	
Q1.1	Please select your country:	1, Albania
		2, Andorra
		3, Armenia
		4, Austria
		5, Azerbaijan
		6, Belarus
		7, Belgium
		8, Bosnia & Herzegovina
		9, Bulgaria
		10, Croatia
		11, Cyprus
		12, Czechia
		13, Denmark
		14, Estonia
		15, Finland
		16, France
		17, Georgia
		18, Germany
		19, Greece
		20, Hungary
		21, Iceland
		22, Ireland
		23, Israel
		24, Italy
		25, Kazakhstan
		26, Kosovo
		27, Kyrgyzstan
		28, Latvia
		29, Liechtenstein
		30, Lithuania
		31, Luxembourg
		32, Malta
		33, Monaco
		34, Montenegro
		35, Netherlands
		36, North Macedonia
		37, Norway
		38, Poland
		39, Portugal
		40, Republic of Moldova
		41, Romania

		42, Russian Federation
		43, San Marino
		44, Serbia
		45, Slovakia
		46, Slovenia
		47, Spain
		48, Sweden
		49, Switzerland
		50, Tajikistan
		51, Turkey
		52, Turkmenistan
		53, Ukraine
		54, United Kingdom of Great Britain and Northern Ireland
		55, Uzbekistan
Q1.2	First name:	
Q1.3	Surname:	
Q1.4	Job Title:	
Q1.5	Email Address:	
Q1.6	Phone Number (optional):	
Q1.6.1	Please upload a full list of staff involved in this submission	
Q1.7	Did representatives from civil society participate in completing this questionnaire?	Yes
		No
Q1.8	Please give details on the nature of involvement:	
Q1.9	First name:	
Q1.10	Surname:	
Q1.11	Job Title:	
Q1.12	Email Address:	
Q1.13	Phone Number:	

## SIZE ESTIMATES FOR KEY POPULATIONS

This form is pre-populated with data reported in the previous data collection round. Previously entered data is shown below each data entry field. Please enter new data if available. If no new data are available, please review and enter the data from the previous dataset in the data entry field.

DDM 2	Question	Response
2.0	Have you estimated the sizes of the following key populations?	Men who have sex with men
		Sex workers
		People in prisons and other closed settings
		Transgender people
		PWID
		Migrants
		No estimates available
	Note: Data older than 5 years will not be accepted	
	<b>Men who have sex with men</b>	
	This indicator is aligned with GAM 1.2B. Guidance on responding to this question is available here.	<a href="https://www.unaids.org/sites/default/files/media_asset/global-aids-monitoring_en.pdf#page=12">https://www.unaids.org/sites/default/files/media_asset/global-aids-monitoring_en.pdf#page=12</a>
2.1.1	Year of latest estimation	
2.1.2	Size estimate	
2.1.3	Upper bound	
2.1.4	Lower bound	
2.1.5	Region for which the last estimation was performed (e.g. for the entire country, for one province, for the capital city, etc.)	
2.1.6	Definition used for the population and inclusion criteria used in the study/survey, as applicable	
2.1.7	Method to derive the size estimate	
2.1.8	Comments and additional information	
2.1.9	If available, upload a relevant supporting document by clicking on the icon. Any file format is acceptable, but it must be less than 8MB in size. When it has uploaded successfully, a unique ID will appear in the box.	
	<b>Sex workers</b>	
	This indicator is aligned with GAM 1.2A. Guidance on responding to this question is available here.	<a href="https://www.unaids.org/sites/default/files/media_asset/global-aids-monitoring_en.pdf#page=12">https://www.unaids.org/sites/default/files/media_asset/global-aids-monitoring_en.pdf#page=12</a>
2.2.1	Year of latest estimation	
2.2.2	Size estimate	
2.2.3	Upper bound	
2.2.4	Lower bound	
2.2.5	Region for which the last estimation was performed (e.g. for the entire country, for one province, for the capital city, etc.)	

2.2.6	Definition used for the population and inclusion criteria used in the study/survey, as applicable	
2.2.7	Method to derive the size estimate	
2.2.8	Comments and additional information	
2.2.9	If available, upload a relevant supporting document by clicking on the icon. Any file format is acceptable, but it must be less than 8MB in size. When it has uploaded successfully, a unique ID will appear in the box.	
	<b>People in prisons and other closed settings</b>	
	This indicator is aligned with GAM 1.2E. Guidance on responding to this question is available here.	<a href="https://www.unaids.org/sites/default/files/media_asset/global-aids-monitoring_en.pdf#page=12">https://www.unaids.org/sites/default/files/media_asset/global-aids-monitoring_en.pdf#page=12</a>
2.3.1	Year of latest estimation	
2.3.2	Size estimate	
2.3.3	Upper bound	
2.3.4	Lower bound	
2.3.5	Region for which the last census was performed (e.g. for the entire country, for one province, for the capital city, etc.)	
2.3.6	Definition used for the population and inclusion criteria used in the study/survey, as applicable	
2.3.7	Method to derive the size estimate	
2.3.8	Comments and additional information	
2.3.9	If available, upload a relevant supporting document by clicking on the icon. Any file format is acceptable, but it must be less than 8MB in size. When it has uploaded successfully, a unique ID will appear in the box.	
	<b>Transgender people</b>	
	This indicator is aligned with GAM 3.2D. Guidance on responding to this question is available here.	
	This indicator is aligned with GAM 1.2D. Guidance on responding to this question is available here.	<a href="https://www.unaids.org/sites/default/files/media_asset/global-aids-monitoring_en.pdf#page=12">https://www.unaids.org/sites/default/files/media_asset/global-aids-monitoring_en.pdf#page=12</a>
2.4.1	Year of latest estimation	
2.4.2	Size estimate	
2.4.3	Upper bound	
2.4.4	Lower bound	
2.4.5	Region for which the last estimation was performed (e.g. for the entire country, for one province, for the capital city, etc.)	
2.4.6	Definition used for the population and inclusion criteria used in the study/survey, as applicable	
2.4.7	Method to derive the size estimate	
2.4.8	Comments and additional information	
2.4.9	If available, upload a relevant supporting document by clicking on the icon. Any file format is acceptable, but it must be less than 8MB in size. When it has uploaded successfully, a unique ID will appear in the box.	

	<b>People who inject drugs</b>	
2.5.1	Year of latest estimation	
2.5.2	Size estimate	
2.5.3	Upper bound	
2.5.4	Lower bound	
2.5.5	Region for which the last estimation was performed (e.g. for the entire country, for one province, for the capital city, etc.)	
2.5.6	Definition used for the population and inclusion criteria used in the study/survey, as applicable	
2.5.7	Method to derive the size estimate	
2.5.8	Comments and additional information	
2.5.9	If available, upload a relevant supporting document by clicking on the icon. Any file format is acceptable, but it must be less than 8MB in size. When it has uploaded successfully, a unique ID will appear in the box.	
	<b>Migrants</b>	
2.6.1	Year of latest estimation	
2.6.2	Size estimate	
2.6.3	Upper bound	
2.6.4	Lower bound	
2.6.5	Region for which the last estimation was performed (e.g. for the entire country, for one province, for the capital city, etc.)	
2.6.6	Definition used for the population and inclusion criteria used in the study/survey, as applicable	
2.6.7	Method to derive the size estimate	
2.6.8	Comments and additional information	
2.6.9	If available, upload a relevant supporting document by clicking on the icon. Any file format is acceptable, but it must be less than 8MB in size. When it has uploaded successfully, a unique ID will appear in the box.	

**HIV PREVALENCE**

This form is pre-populated with data reported in the previous data collection round. Previously entered data is shown below each data entry field. Please enter new data if available. If no new data are available, please review and enter the data from the previous dataset in the data entry field.

DDM 202	Question	Response
	<b>This indicator is aligned with GAM 1.3 (A-E). Guidance on responding to this question is available <a href="https://www.unaids.org/sites/default/files/media_asset/global-aids-monitoring_en.pdf#page=14">here</a>.</b>	<a href="https://www.unaids.org/sites/default/files/media_asset/global-aids-monitoring_en.pdf#page=14">https://www.unaids.org/sites/default/files/media_asset/global-aids-monitoring_en.pdf#page=14</a>
3.0.1	Select the populations for which you have prevalence data:	Men who have sex with men
		People who inject drugs
		Migrants
		Sex workers
		People in prisons and other closed settings
		Transgender people
		No additional data
	<b>Men who have sex with men</b>	
3.1.1	Data measurement tool:	National programme data
		Sentinel surveillance
		Behavioural Surveillance Survey (please specify sampling strategy and location)
		Special Study (please specify sampling strategy and location)
		Other (please specify sampling strategy and location)
3.1.1.1	Please specify sampling strategy and location:	
3.1.2	Data Collection Period From:	
3.1.3	Data Collection Period To:	
3.1.4	Additional information related to entered data. e.g. reference to primary data source, methodological concerns:	
3.1.4.1	If available, upload a relevant supporting document by clicking on the icon. Any file format is acceptable, but it must be less than 8MB in size. When it has uploaded successfully, a unique ID will appear in the box.	
3.1.5	Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source:	
3.1.6	Sample size - Number of Survey Respondents	
3.1.7	<b>HIV prevalence among men who have sex with men</b>	
	<b>Number of men who have sex with men who test positive for HIV</b>	
3.1.7	All	
3.1.8	<25	
3.1.11	25+	
	<b>Number of men who have sex with men tested for HIV</b>	
3.1.7.1	All	
3.1.9	<25	
3.1.12	25+	
	<b>Percentage of men who have sex with men living with HIV</b>	
3.1.7.2	All	#DIV/0!
3.1.10	<25	#DIV/0!

3.1.13	25+	#DIV/0!
	<b>People who inject drugs</b>	
3.2.1	Data measurement tool:	National programme data
		Sentinel surveillance
		Behavioural Surveillance Survey (please specify sampling strategy and location)
		Special Study (please specify sampling strategy and location)
		Other (please specify sampling strategy and location)
3.2.1.1	Please specify sampling strategy and location:	
3.2.2	Data Collection Period From:	
3.2.3	Data Collection Period To:	
3.2.4	Additional information related to entered data. e.g. reference to primary data source, methodological concerns:	
3.2.4.1	If available, upload a relevant supporting document by clicking on the icon. Any file format is acceptable, but it must be less than 8MB in size. When it has uploaded successfully, a unique ID will appear in the box.	
3.2.5	Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source:	
3.2.6	Sample size - Number of Survey Respondents	
3.2.7	<b>HIV prevalence among people who inject drugs</b>	
	<b>Numerator: Number of people who inject drugs who test positive for HIV</b>	
3.2.7	All	
3.2.8	Males	
3.2.9	Females	
3.2.10	Transgender people	
3.2.11	<25	
3.2.12	25+	
	<b>Denominator: Number of people who inject drugs tested for HIV</b>	
3.2.7.1	All	
3.2.8.1	Males	
3.2.9.1	Females	
3.2.10.1	Transgender people	
3.2.11.1	<25	
3.2.12.1	25+	
	<b>Percentage of people who inject drugs living with HIV</b>	
3.2.7.2	All	#DIV/0!
3.2.8.2	Males	#DIV/0!
3.2.9.2	Females	#DIV/0!
3.2.10.2	Transgender people	#DIV/0!
3.2.11.2	<25	#DIV/0!
3.2.12.2	25+	#DIV/0!
	<b>Migrants</b>	
3.3.1	Data measurement tool:	National programme data
		Sentinel surveillance
		Behavioural Surveillance Survey (please specify sampling strategy and location)
		Special Study (please specify sampling strategy and location)
		Other (please specify sampling strategy and location)



3.3.1.1	Please specify sampling strategy and location:	
3.3.2	Data Collection Period From:	
3.3.3	Data Collection Period To:	
3.3.4	In this questionnaire, migrants are defined as persons born abroad. If your prevalence data refers only to a subgroup of migrants within this definition, please specify which subgroup here:	
3.3.5	Additional information related to entered data. e.g. reference to primary data source, methodological concerns:	
3.3.5.1	If available, upload a relevant supporting document by clicking on the icon. Any file format is acceptable, but it must be less than 8MB in size. When it has uploaded successfully, a unique ID will appear in the box.	
3.3.6	Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source:	
3.3.7	Sample size - Number of Survey Respondents	
3.3.8	<b>HIV prevalence among migrants</b>	
	<b>Numerator: Number of migrants who test positive for HIV</b>	
3.3.8	All	
3.3.9	Males	
3.3.12	Females	
3.3.15	Transgender people	
3.3.18	<25	
3.3.21	25+	
	<b>Denominator: Number of migrants tested for HIV</b>	
3.3.8.1	All	
3.3.10	Males	
3.3.13	Females	
3.3.16	Transgender people	
3.3.19	<25	
3.3.22	25+	
	<b>Percentage of migrants living with HIV</b>	
3.3.8.2	All	#DIV/0!
3.3.11	Males	#DIV/0!
3.3.14	Females	#DIV/0!
3.3.17	Transgender people	#DIV/0!
3.3.20	<25	#DIV/0!
3.3.23	25+	#DIV/0!
	<b>Sex workers</b>	
3.4.1	Data measurement tool:	National programme data
		Sentinel surveillance
		Behavioural Surveillance Survey (please specify sampling strategy and location)
		Special Study (please specify sampling strategy and location)
		Other (please specify sampling strategy and location)
3.4.1.1	Please specify sampling strategy and location:	
3.4.2	Data Collection Period From:	
3.4.3	Data Collection Period To:	

3.4.4	Additional information related to entered data. e.g. reference to primary data source, methodological concerns:	
3.4.4.1	If available, upload a relevant supporting document by clicking on the icon. Any file format is acceptable, but it must be less than 8MB in size. When it has uploaded successfully, a unique ID will appear in the box.	
3.4.5	Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source:	
3.4.6	Sample size - Number of Survey Respondents	
3.4.7	<b>HIV prevalence among sex workers</b>	
	<b>Number of sex workers who test positive for HIV</b>	
3.4.7	All	
3.4.10	Males	
3.4.13	Females	
3.4.16	Transgender people	
3.4.19	<25	
3.4.22	25+	
	<b>Number of sex workers tested for HIV</b>	
3.4.8	All	
3.4.11	Males	
3.4.14	Females	
3.4.17	Transgender people	
3.4.20	<25	
3.4.23	25+	
	<b>Percentage of sex workers living with HIV</b>	
3.4.9	All	#DIV/0!
3.4.12	Males	#DIV/0!
3.4.15	Females	#DIV/0!
3.4.18	Transgender people	#DIV/0!
3.4.21	<25	#DIV/0!
3.4.24	25+	#DIV/0!
	<b>People in prisons and other closed settings</b>	
3.5.1	Data measurement tool:	HIV tests conducted by jails, prisons and other closed settings
		Programme data
		Other (please specify)
3.5.1.1	Please specify sampling strategy and location:	
3.5.2	Data Collection Period From:	
3.5.3	Data Collection Period To:	
3.5.4	Additional information related to entered data. e.g. reference to primary data source, methodological concerns:	
3.5.4.1	If available, upload a relevant supporting document by clicking on the icon. Any file format is acceptable, but it must be less than 8MB in size. When it has uploaded successfully, a unique ID will appear in the box.	
3.5.5	Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source:	
3.5.6	<b>Sample size - Number of Survey Respondents</b>	
3.5.7	<b>HIV prevalence among prisoners/inmates/detainees</b>	

	<b>Number of prisoners/inmates/detainees who test positive for HIV</b>	
3.5.7	All	
3.5.10	Males	
3.5.13	Females	
3.5.16	Transgender people	
3.5.19	<25	
3.5.22	25+	
	<b>Number of prisoners/inmates/detainees tested for HIV</b>	
3.5.8	All	
3.5.11	Males	
3.5.14	Females	
3.5.17	Transgender people	
3.5.20	<25	
3.5.23	25+	
	<b>Percentage of prisoners/inmates/detainees living with HIV</b>	
3.5.9	All	#DIV/0!
3.5.12	Males	#DIV/0!
3.5.15	Females	#DIV/0!
3.5.18	Transgender people	#DIV/0!
3.5.21	<25	#DIV/0!
3.5.24	25+	#DIV/0!
	<b>Transgender people</b>	
3.6.1	Data measurement tool:	National programme data
		Sentinel surveillance
		Behavioural Surveillance Survey (please specify sampling strategy and location)
		Special Study (please specify sampling strategy and location)
		Other (please specify sampling strategy and location)
3.6.1.1	Please specify sampling strategy and location:	
3.6.2	Data Collection Period From:	
3.6.3	Data Collection Period To:	
3.6.4	Additional information related to entered data. e.g. reference to primary data source, methodological concerns:	
3.6.4.1	If available, upload a relevant supporting document by clicking on the icon. Any file format is acceptable, but it must be less than 8MB in size. When it has uploaded successfully, a unique ID will appear in the box.	
3.6.5	Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source:	
3.6.6	Sample size - Number of Survey Respondents	
3.6.7	<b>HIV prevalence among transgender people</b>	
	<b>Numerator: Number of transgender people who test positive for HIV</b>	
3.6.7.1	All	
3.6.9	Transman	
3.6.12	Transwoman	
3.6.15	Other	
3.6.18	<25	

3.6.21	25+	
	<b>Denominator: Number of transgender people tested for HIV</b>	
3.6.7	All	
3.6.10	Transman	
3.6.13	Transwoman	
3.6.16	Other	
3.6.19	<25	
3.6.22	25+	
	<b>Percentage of transgender people living with HIV</b>	
3.6.8	All	#DIV/0!
3.6.11	Transman	#DIV/0!
3.6.14	Transwoman	#DIV/0!
3.6.17	Other	#DIV/0!
3.6.20	<25	#DIV/0!
3.6.23	25+	#DIV/0!
3.7	Any further comments?	

LAWS AND POLICIES

This form is pre-populated with data reported in the previous data collection round. Previously entered data is shown below each data entry field. Please enter new data if available. If no new data are available, please review and enter the data from the previous dataset in the data entry field.

DDM 2024	Question	Response
6.1	Do the following key populations participate* in developing national policies, guidelines and strategies relating to their health in your country?	MSM
		Former and/or current sex workers
		Former and/or current PWID
		Transgender people
		Former and/or current people in prisons and other closed settings
		Migrants
		None of the above
	<p>* Defined by UNAIDS as 'Active and informed participation in formulating, implementing, monitoring and evaluating all decisions, policies and interventions that affect one’s health to ensure respect for human rights. It also means ensuring that health systems and interventions are responsive, effective, appropriate and sustainable. Participation is informed when people can access the information required to participate in a meaningful and effective way. If necessary, capacity-building activities should be carried out to ensure this.'</p>	
6.2	Are there any laws or policies protecting PLHIV from discrimination in the following areas?	Employment
		Healthcare
		Education
		Private services
		Public services (including social security, criminal justice, public housing, etc.)
6.2.1		Other (please specify)
6.3	Does your country have laws criminalizing the transmission of, non-disclosure of or exposure to HIV transmission?	Yes
		No, but prosecutions occur based on general criminal laws
		No
6.4	Do travel or visa laws in your country discriminate against PLHIV?	Yes
		No
6.5	Are transgender people criminalized and/or prosecuted because of their gender identity in your country?	Both criminalized and prosecuted
		Criminalized
		Prosecuted
		Neither criminalized nor prosecuted
6.6	Does your country have punitive laws affecting lesbian, gay, bisexual, transgender and intersex (LGBTI) people?	Yes, laws criminalising same-sex sexual acts
		Yes, promotion (“propaganda”) laws
		Yes, morality laws or religious norms that limit lesbian, gay, bisexual, transgender and intersex freedom of expression and association
6.6.1		Yes, others (please specify): _____
		No
6.7	Does your country have any of the following legal protections for transgender people (please select all that apply)?	Constitutional prohibition of discrimination based on sex

		Constitutional prohibition of discrimination based on gender diversity
		Constitutional prohibition of discrimination based on any grounds
		Prohibitions of discrimination in employment based on gender diversity
		A third gender is legally recognized
		Other non-discrimination provisions specifying gender diversity
		No
6.8	Does your country have any laws or other provisions specifying protections based on grounds of sexual orientation (please select all that apply):	Constitutional prohibition of discrimination based on sexual orientation
		Constitutional prohibition of discrimination based on sex
		Constitutional prohibition of discrimination based on any grounds
		Hate crimes based on sexual orientation considered an aggravating circumstance
		Incitement to hatred based on sexual orientation prohibited
		Prohibition of discrimination in employment based on sexual orientation
		Other non-discrimination provisions specifying sexual orientation
		No
6.9	Is sex work criminalized in your country (select all that apply)?	Selling sexual services is criminalized
		Buying sexual services is criminalized
		Ancillary activities associated with selling sexual services are criminalized
		Ancillary activities associated with buying sexual services are criminalized
		Profiting from organizing and/or managing sexual services is criminalized
		Other punitive and/or administrative regulation of sex work
		Sex work is not subject to punitive regulations and is not criminalized
		Issue is determined/differs at subnational level
6.10	Is drug use or possession for personal use an offence in your country (please select all that apply)?	The law allows possession of a certain amount of drugs
		Drug use or consumption is specified as a criminal offence
		Drug use or consumption is specified as a non-criminal offence
		Possession of drugs for personal use is specified as a criminal offence
		Possession of drugs for personal use is specified as a non-criminal offence
		No
6.11	Is there explicit supportive reference to harm reduction in national policies?	Yes
		No
6.12	Any further comments?	

**HIV PREVENTION POLICY AND PROVISION**

This form is pre-populated with data reported in the previous data collection round. Previously entered data is shown below each data entry field. Please enter new data if available. If no new data are available, please review and enter the data from the previous dataset in the data entry field.

DDM 2024	Question	Response
8.1.1	Is there a national prevention strategy to reduce new HIV infections in your country?	Yes
		No
8.1.1.1	If yes, is this strategy budgeted for and implemented in your country?	Yes
		No
8.1.1.2		Other (please specify)
8.1.1.3	If there is not a strategy, are there plans in place to develop one?	Yes
		No
8.1.1.4		Other (please specify)
8.1.2	If yes, does it mention or specifically focus on any of the following key populations?	
		MSM
		PWID
		Migrants
		Undocumented migrants
		Sex workers
		Prisoners
		Trans people
		Other (please specify)
		None of the above
8.1.2.1	Please specify:	
	<b>Condoms</b>	
8.1.3	Are condoms and lubricants available free to the following key populations in your country?	
		General population
		MSM
		PWID
		Migrants
		Undocumented migrants
		Sex workers
		Prisons
		Transgender people
		Other (please specify)
		None of the above
8.1.3.1	Please specify:	
	<b>STI testing and treatment</b>	
8.1.4	Does your country have national treatment guidelines or recommendations for sexually transmitted infections (STIs)?	Yes
		No
8.1.5	If yes, in what year were they last updated? _____	
8.1.6	Does your country have a national strategy or action plan for the prevention and control of STIs?	Yes

		No
8.1.7	Are STI testing and treatment services available to the following key populations in your country?	
8.1.7	General population	Available free
		Free if the individual has insurance
		Available at a cost
		Not available
8.1.7.1	MSM	Available free
		Free if the individual has insurance
		Available at a cost
		Not available
8.1.7.2	PWID	Available free
		Free if the individual has insurance
		Available at a cost
		Not available
8.1.7.3	Migrants	Available free
		Free if the individual has insurance
		Available at a cost
		Not available
8.1.7.4	Undocumented migrants	Available free
		Free if the individual has insurance
		Available at a cost
		Not available
8.1.7.5	Sex workers	Available free
		Free if the individual has insurance
		Available at a cost
		Not available
8.1.7.6	Prisoners	Available free
		Free if the individual has insurance
		Available at a cost
		Not available
8.1.7.7	Transgender people	Available free
		Free if the individual has insurance
		Available at a cost
		Not available
8.1.8	Any further comments?	



SEXUALITY EDUCATION

This form is pre-populated with data reported in the previous data collection round. Previously entered data is shown below each data entry field. Please enter new data if available. If no new data are available, please review and enter the data from the previous dataset in the data entry field.

DDM 2024	Question	Response
8.2.1	Does your country have education policies that guide the delivery of life skills-based HIV and sexuality education*, according to international standards**, in:	
Q8.2.1	Primary school	Yes
		No
Q8.2.1.1	Secondary school	Yes
		No
Q8.2.1.2	University	Yes
		No
Q8.2.1.3	Teacher training	Yes
		No
	* An age-appropriate, culturally relevant approach to teaching about sex and relationships by providing scientifically accurate, realistic and non-judgemental information (for more information see UNESCO, UNAIDS, UNFPA, UNICEF, WHO. International technical guidance on sexuality education. Volume I. Paris: UNESCO; 2009.)	
	** Standardized UNESCO benchmarks for the sexuality education curriculum to ensure quality, including teaching on (1) generic life skills (such as decisionmaking, communication and negotiating skills); (2) sexual and reproductive health and sexuality education (such as human growth and development, relationships, reproductive health, sexual abuse and transmission of sexually transmitted infections); and (3) HIV transmission and prevention.	

## Coverage of HIV prevention programmes among men who have sex with men

This form is pre-populated with data reported in the previous data collection round. Previously entered data is shown below each data entry field. Please enter new data if available. If no new data are available, please review and enter the data from the previous dataset in the data entry field.

DDM 2024	Question	Response
	This indicator is aligned with GAM 1.6B. Guidance on responding to this question is available here.	<a href="https://www.unaids.org/sites/default/files/media_asset/global-aids-monitoring_en.pdf#page=26">https://www.unaids.org/sites/default/files/media_asset/global-aids-monitoring_en.pdf#page=26</a>
8.3	Are data available?	Yes
		No
8.3.1	What type of data are available? Please select all that apply:	Behavioural Surveillance Survey
	Note: If you have survey and/or programme data, this is preferred to expert opinion.	Special study or other survey
		Programme data
		Expert opinion
8.3.1.1		Other
	Please specify sampling strategy and location:	
8.3.2	Data Collection Period From:	
8.3.3	Data Collection Period To:	
8.3.4	<b>Additional information related to entered data. e.g. reference to primary data source, methodological concerns, varying timeframes, etc:</b>	
8.3.4.1	If available, upload a relevant supporting document by clicking on the icon. Any file format is acceptable, but it must be less than 8MB in size. When it has uploaded successfully, a unique ID will appear in the box.	
8.3.5	Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source:	
	<b>I. Behavioural surveillance or other special surveys</b>	
8.3.6	Please specify sampling strategy and location:	
8.3.7	Sample size - Number of Survey Respondents	

8.3.8	For which survey questions are you able to provide data on men who have sex with men? Please select all that apply:	In the past three months, have you been given condoms and lubricant (for example, through an outreach service, drop-in centre or sexual health clinic)?
		In the past three months, have you received counselling on condom use and safe sex (for example, through an outreach service, drop-in centre or sexual health clinic)?
		Have you been tested for sexually transmitted infections in the past three months?
		Percentage of respondents who report receiving at least two of the above-mentioned HIV prevention services from a nongovernmental organization, health-care provider or other sources
	Please provide any data available, including disaggregations by age if available.	
8.3.9	<b>Table A. In the past three months, have you been given condoms and lubricant (for example, through an outreach service, drop-in centre or sexual health clinic)?</b>	
	<b>Numerator: Number of men who have sex with men who answered "yes"</b>	
8.3.9.1	All	
8.3.9.4	<25	
8.3.9.7	25+	
	<b>Denominator: Number of men who have sex with men responding to the survey</b>	
8.3.9.2	All	
8.3.9.5	<25	
8.3.9.8	25+	

	<b>Percentage (%): Percentage of respondents who answered "yes" to the question "In the past three months, have you been given condoms and lubricant (for example, through an outreach service, drop-in centre or sexual health clinic)?"</b>	
8.3.9.3	All	#DIV/0!
8.3.9.6	<25	#DIV/0!
8.3.9.9	25+	#DIV/0!
8.3.10	<b>Table B. In the past three months, have you received counselling on condom use and safe sex (for example, through an outreach service, drop-in centre or sexual health clinic)?</b>	
	<b>Numerator: Number of men who have sex with men who answered "yes"</b>	
8.3.10	All	
8.3.10.3	<25	
8.3.10.6	25+	
	<b>Denominator: Number of men who have sex with men responding to the survey</b>	
8.3.10.1	All	
8.3.10.4	<25	
8.3.10.7	25+	
	<b>Percentage (%): Percentage of respondents who answered "yes" to the question "In the past three months, have you received counselling on condom use and safe sex (for example, through an outreach service, drop-in centre or sexual health clinic)?"</b>	
8.3.10.2	All	#DIV/0!
8.3.10.5	<25	#DIV/0!
8.3.10.8	25+	#DIV/0!
8.3.11	<b>Table C. Have you been tested for sexually transmitted infections in the past three months?</b>	
	<b>Numerator: Number of men who have sex with men who answered "yes" to the question "Have you been tested for sexually transmitted infections in the past three months?"</b>	
8.3.11	All	
8.3.11.3	<25	
8.3.12.6	25+	
	<b>Denominator: Number of men who have sex with men responding to the survey</b>	
8.3.11.1	All	

8.3.11.4	<25	
8.3.11.7	25+	
	Percentage (%): Percentage of respondents who answered "yes" to the question "Have you been tested for sexually transmitted infections in the past three months?"	
8.3.11.2	All	#DIV/0!
8.3.11.5	<25	#DIV/0!
8.3.11.8	25+	#DIV/0!
8.3.12	Table D. Percentage of respondents who report receiving at least two of the above-mentioned HIV prevention services from a nongovernmental organization, health-care provider or other sources	
	Numerator: Number of men who have sex with men who report receiving at least two of the above-mentioned HIV prevention services from a nongovernmental organization, health-care provider or other sources	
8.3.12	All	
8.3.12.3	<25	
8.3.12.6	25+	
	Denominator: Number of men who have sex with men responding to the survey	
8.3.12.1	All	
8.3.12.4	<25	
8.3.12.7	25+	
	Percentage (%): Percentage of men who have sex with men who report receiving at least two of the above-mentioned HIV prevention services from a nongovernmental organization, health-care provider or other sources	
8.3.12.2	All	#DIV/0!
8.3.12.5	<25	#DIV/0!
8.3.12.8	25+	#DIV/0!
II. Programme data		
	Please provide any data available, including disaggregations by provider if available. For a definition of key-population led organisations, see UNAIDS guidance here. 'Other entities' could include private for-profit and non-profit organisations which are not key-population led, including national and international nongovernmental organisations.	<a href="https://www.unaids.org/sites/default/files/media_asset/global-aids-monitoring_en.pdf#page=34">https://www.unaids.org/sites/default/files/media_asset/global-aids-monitoring_en.pdf#page=34</a>

8.3.13	<b>Proportion of men who have sex with men who are reached with HIV prevention interventions designed for men who have sex with men</b>	
	<b>Numerator: Number of men who have sex with men reached with HIV prevention interventions designed for men who have sex with men</b>	
8.3.13	Total	
8.3.13.4	Public Sector	
8.3.13.8	Key populations-led organization	
8.3.13.12	Other entities	
	<b>Denominator: Number of men who have sex with men</b>	
8.3.13.1	Total	
8.3.13.5	Public Sector	
8.3.13.9	Key populations-led organization	
8.3.13.13	Other entities	
	<b>Percentage (%): Percent of men who have sex with men who are reached with HIV prevention interventions designed for men who have sex with men</b>	
8.3.13.2	Total	#DIV/0!
8.3.13.6	Public Sector	#DIV/0!
8.3.13.10	Key populations-led organization	#DIV/0!
8.3.13.14	Other entities	#DIV/0!
	<b>Number of condoms and lubricants distributed</b>	
8.3.13.3	Total	
8.3.13.7	Public Sector	
8.3.13.11	Key populations-led organization	
8.3.13.15	Other entities	
	<b>III. Number of service provision sites dedicated to men who have sex with men</b>	
8.3.14	Total number of service provision sites	
8.3.14.1	1. Sites operated by the national programme (government)	
8.3.14.2	2. Sites operated by the community (civil society or nongovernmental organization)	
8.3.15	Number of peer outreach workers active at the time of reporting	
8.3.16	Number of administrative areas with service provision sites	
8.3.17	Total number of administrative areas in the country	
	<b>IV. Expert opinion on HIV prevention programme coverage for men who have sex with men</b>	

	If you are unable to provide survey or programme data on coverage of HIV prevention programmes for men who have sex with men, please provide responses based on expert opinion with an explanation of how you reached this answer.	
	Based on the WHO definition of universal health coverage, full coverage was defined as 'all who need the service can use it, that the service is of sufficient quality to be effective, and that use of the service will not expose the user to financial hardship'. Countries could choose from a scale of coverage, as follows: No coverage: The service is not provided; Low coverage: <30% of the population can use the effective, affordable service; Medium coverage: 30-60% of the population can use the effective, affordable service; High coverage: 61-95% of the population can use the effective, affordable service; Full coverage: 95-100% of the population can use the effective, affordable service.	
8.3.18	What is the estimated coverage of condom and lubricant programmes among men who have sex with men in your country?	Full coverage (95-100%)
		High coverage (61-95%)
		Medium coverage (30-60%)
		Low coverage (<30%)
		No coverage (service not provided)
8.3.18.1	Please explain how you reached this answer:	
8.3.19	What is the estimated coverage of counselling on condom use and safe sex for men who have sex with men in your country?	Full coverage (95-100%)
		High coverage (61-95%)
		Medium coverage (30-60%)
		Low coverage (<30%)
		No coverage (service not provided)
8.3.19.1	Please explain how you reached this answer:	[Open text]
8.3.20	What is the estimated coverage of STI testing for men who have sex with men in your country?	Full coverage (95-100%)
		High coverage (61-95%)

		Medium coverage (30-60%)
		Low coverage (<30%)
		No coverage (service not provided)
8.3.20.1	Please explain how you reached this answer:	







Coverage of HIV prevention programmes among people who inject drugs

This form is pre-populated with data reported in the previous data collection round. Previously entered data is shown below each data entry field. Please enter new data if available. If no new data are available, please review and enter the data from the previous dataset in the data entry field.

DDM 2024	Question	Response
	This indicator is aligned with GAM 1.6C. Guidance on responding to this question is available here.	<a href="https://www.unaids.org/sites/default/files/media_asset/global-aids-monitoring_en.pdf#page=26">https://www.unaids.org/sites/default/files/media_asset/global-aids-monitoring_en.pdf#page=26</a>
8.4	Are data available?	Yes
		No
8.4.1	What type of data are available? Please select all that apply:	Behavioural Surveillance Survey
	Note: If you have survey and/or programme data, this is preferred to expert opinion.	Special study or other survey
		Programme data
		Expert opinion
8.4.1.1		Other
	Please specify sampling strategy and location:	
8.4.2	Data Collection Period From:	
8.4.3	Data Collection Period To:	
8.4.4	Additional information related to entered data. e.g. reference to primary data source, methodological concerns:	
8.4.4.1	If available, upload a relevant supporting document by clicking on the icon. Any file format is acceptable, but it must be less than 8MB in size. When it has uploaded successfully, a unique ID will appear in the box.	
8.4.5	Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source:	
	I. Behavioural surveillance or other special surveys	
8.4.6	Please specify sampling strategy and location:	
8.4.7	Sample size - Number of Survey Respondents	
8.4.8	For which survey questions are you able to provide data on people who inject drugs? Please select all that apply:	In the past three months, have you been given condoms and lubricant (for example, through an outreach service, drop-in centre or sexual health clinic)?
		In the past three months, have you received counselling on condom use and safe sex (for example, through an outreach service, drop-in centre or sexual health clinic)?
		Have you received new, clean needles and syringes in the past three months?
		Percentage of respondents who report receiving at least two of the above-mentioned HIV prevention services from a nongovernmental organization, health-care provider or other sources
	Please provide any data available, including disaggregations by age, sex and transgender if available.	

8.4.9	Table A. In the past three months, have you been given condoms and lubricant (for example, through an outreach service, drop-in centre or sexual health clinic)?	
	Numerator: Number of people who inject drugs who answered "yes"	
8.4.9	All	
8.4.9.3	Males	
8.4.9.6	Females	
8.4.6.9	Transgender	
8.4.6.12	<25	
8.4.6.15	25+	
	Denominator: Number of people who inject drugs responding to the survey	
8.4.9.1	All	
8.4.9.4	Males	
8.4.9.7	Females	
8.4.6.10	Transgender	
8.4.6.13	<25	
8.4.6.16	25+	
	Percentage (%): Percentage of respondents who answered "yes" to the question "In the past three months, have you been given condoms and lubricant (for example, through an outreach service, drop-in centre or sexual health clinic)?"	
8.4.9.2	All	#DIV/0!
8.4.9.5	Males	
8.4.9.8	Females	
8.4.6.11	Transgender	
8.4.6.14	<25	#DIV/0!
8.4.6.17	25+	#DIV/0!
8.4.10	Table B. In the past three months, have you received counselling on condom use and safe sex (for example, through an outreach service, drop-in centre or sexual health clinic)?	
	Numerator: Number of people who inject drugs who answered "yes"	
8.4.10	All	
8.4.10.3	Males	
8.4.10.6	Females	
8.4.10.9	Transgender	
8.4.10.12	<25	
8.4.10.15	25+	
	Denominator: Number of people who inject drugs responding to the survey	
8.4.10.1	All	
8.4.10.4	Males	
8.4.10.7	Females	
8.4.10.10	Transgender	
8.4.10.13	<25	
8.4.10.16	25+	
	Percentage (%): Percentage of respondents who answered "yes" to the question "In the past three months, have you received counselling on condom use and safe sex (for example, through an outreach service, drop-in centre or sexual health clinic)?"	
8.4.10.2	All	#DIV/0!
8.4.10.5	Males	
8.4.10.8	Females	
8.4.10.11	Transgender	
8.4.10.14	<25	#DIV/0!
8.4.10.17	25+	#DIV/0!

8.4.11	Table C. Have you received new, clean needles and syringes in the past three months?	
	Numerator: Number of people who inject drugs who answered "yes" to the question "Have you received new, clean needles and syringes in the past three months?"	
8.4.11	All	
8.4.11.3	Males	
8.4.11.6	Females	
8.4.11.9	Transgender	
8.4.11.12	<25	
8.4.11.15	25+	
	Denominator: Number of people who inject drugs responding to the survey	
8.4.11.1	All	
8.4.11.4	Males	
8.4.11.7	Females	
8.4.11.10	Transgender	
8.4.11.13	<25	
8.4.11.16	25+	
	Percentage (%): Percentage of respondents who answered "yes" to the question "Have you received new, clean needles and syringes in the past three months?"	
8.4.11.2	All	#DIV/0!
8.4.11.5	Males	
8.4.11.8	Females	
8.4.11.11	Transgender	
8.4.11.14	<25	#DIV/0!
8.4.11.17	25+	#DIV/0!
8.4.12	Table D. Percentage of respondents who report receiving at least two of the above-mentioned HIV prevention services from a nongovernmental organization, health-care provider or other sources	
	Numerator: Number of people who inject drugs who report receiving at least two of the above-mentioned HIV prevention services from a nongovernmental organization, health-care provider or other sources	
8.4.12	All	
8.4.12.3	Males	
8.4.12.6	Females	
8.4.12.9	Transgender	
8.4.12.12	<25	
8.4.12.15	25+	
	Denominator: Number of people who inject drugs responding to the survey	
8.4.12.1	All	
8.4.12.4	Males	
8.4.12.7	Females	
8.4.12.10	Transgender	
8.4.12.13	<25	
8.4.12.16	25+	
	Percentage (%): Percentage of people who inject drugs who report receiving at least two of the above-mentioned HIV prevention services from a nongovernmental organization, health-care provider or other sources	
8.4.12.2	All	#DIV/0!
8.4.12.5	Males	
8.4.12.8	Females	
8.4.12.11	Transgender	
8.4.12.14	<25	#DIV/0!
8.4.12.17	25+	#DIV/0!

	<b>II. Programme data</b>	
	Please provide any data available, including disaggregations by provider if available. For a definition of key-population led organisations, see UNAIDS guidance here. 'Other entities' could include private for-profit and non-profit organisations which are not key-population led, including national and international nongovernmental organisations.	<a href="https://www.unaids.org/sites/default/files/media_asset/global-aids-monitoring_en.pdf#page=34">https://www.unaids.org/sites/default/files/media_asset/global-aids-monitoring_en.pdf#page=34</a>
8.4.13	<b>Proportion of people who inject drugs who are reached with HIV prevention interventions designed for people who inject drugs</b>	
	<b>Numerator: Number of people who inject drugs reached with HIV prevention interventions designed for people who inject drugs</b>	
8.4.13	Total	
8.4.13.4	Public Sector	
8.4.13.8	Key populations-led organization	
8.4.13.12	Other entities	
	<b>Denominator: Number of people who inject drugs</b>	
8.4.13.1	Total	
8.4.13.5	Public Sector	
8.4.13.9	Key populations-led organization	
8.4.13.13	Other entities	
	<b>Percentage (%): Percent of people who inject drugs who are reached with HIV prevention interventions designed for people who inject drugs</b>	
8.4.13.2	Total	#DIV/0!
8.4.13.6	Public Sector	#DIV/0!
8.4.13.10	Key populations-led organization	#DIV/0!
8.4.13.14	Other entities	#DIV/0!
	<b>III. Number of service provision sites dedicated to people who inject drugs</b>	
8.4.14	Total number of service provision sites	
8.4.14.1	1. Sites operated by the national programme (government)	
8.4.14.2	2. Sites operated by the community (civil society or nongovernmental organization)	
8.4.15	Number of peer outreach workers active at the time of reporting	
8.4.16	Number of administrative areas with service provision sites	
8.4.17	Total number of administrative areas in the country	
	<b>IV. Expert opinion on HIV prevention programme coverage for people who inject drugs</b>	
	If you are unable to provide survey or programme data on coverage of HIV prevention programmes for people who inject drugs, please provide responses based on expert opinion with an explanation of how you reached this answer.	
	Based on the WHO definition of universal health coverage, full coverage was defined as 'all who need the service can use it, that the service is of sufficient quality to be effective, and that use of the service will not expose the user to financial hardship'. Countries could choose from a scale of coverage, as follows: No coverage: The service is not provided; Low coverage: <30% of the population can use the effective, affordable service; Medium coverage: 30-60% of the population can use the effective, affordable service; High coverage: 61-95% of the population can use the effective, affordable service; Full coverage: 95-100% of the population can use the effective, affordable service.	
8.4.18	What is the estimated coverage of condom and lubricant programmes among people who inject drugs in your country?	Full coverage (95-100%)
		High coverage (61-95%)
		Medium coverage (30-60%)
		Low coverage (<30%)
		No coverage (service not provided)

8.4.18.1	Please explain how you reached this answer:	
8.4.19	What is the estimated coverage of counselling on condom use and safe sex for people who inject drugs in your country?	Full coverage (95-100%)
		High coverage (61-95%)
		Medium coverage (30-60%)
		Low coverage (<30%)
		No coverage (service not provided)
8.4.19.1	Please explain how you reached this answer:	

Coverage of HIV prevention programmes among migrants (persons born abroad)		
	This form is pre-populated with data reported in the previous data collection round. Previously entered data is shown below each data entry field. Please enter new data if available. If no new data are available, please review and enter the data from the previous dataset in the data entry field.	
DDM 2024	Question	Response
Q8.5	Are data available?	Yes
		No
Q8.5.1	What type of data are available? Please select all that apply:	Behavioural Surveillance Survey
	Note: If you have survey and/or programme data, this is preferred to expert opinion.	Special study or other survey
		Programme data
		Expert opinion
8.5.1.1		Other
	Please specify sampling strategy and location:	
Q8.5.2	Data Collection Period From:	
Q8.5.3	Data Collection Period To:	
Q8.5.4	Additional information related to entered data. e.g. reference to primary data source, methodological concerns:	[Open text]
Q8.5.4.1	If available, upload a relevant supporting document by clicking on the icon. Any file format is acceptable, but it must be less than 8MB in size. When it has uploaded successfully, a unique ID will appear in the box.	
Q8.5.5	Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source:	[Open text]
	I. Behavioural surveillance or other special surveys	
Q8.5.6	Please specify sampling strategy and location:	
Q8.5.7	Sample size - Number of Survey Respondents	
Q8.5.8	For which survey questions are you able to provide data on migrants? Please select all that apply:	In the past three months, have you been given condoms and lubricant (for example, through an outreach service, drop-in centre or sexual health clinic)?
		In the past three months, have you received counselling on condom use and safe sex (for example, through an outreach service, drop-in centre or sexual health clinic)?
		Have you been tested for sexually transmitted infections in the past three months?
		Percentage of respondents who report receiving at least two of the above-mentioned HIV prevention services from a nongovernmental organization, health-care provider or other sources
	Please provide any data available, including disaggregations by age, sex and transgender if available.	
Q8.5.9	Table A. In the past three months, have you been given condoms and lubricant (for example, through an outreach service, drop-in centre or sexual health clinic)?	
	Numerator: Number of migrants who answered "yes"	
Q8.5.9	All	



Q8.5.9.3	Males	
Q8.5.9.6	Females	
Q8.5.9.9	Transgender	
Q8.5.9.12	<25	
Q8.5.9.15	25+	
Q8.5.9.18	Undocumented migrants	
	Denominator: Number of migrants responding to the survey	
Q8.5.9.1	All	
Q8.5.9.4	Males	
Q8.5.9.7	Females	
Q8.5.9.10	Transgender	
Q8.5.9.13	<25	
Q8.5.9.16	25+	
Q8.5.9.19	Undocumented migrants	
	Percentage (%): Percentage of respondents who answered "yes" to the question "In the past three months, have you been given condoms and lubricant (for example, through an outreach service, drop-in centre or sexual health clinic)?"	
Q8.5.9.2	All	#DIV/0!
Q8.5.9.5	Males	#DIV/0!
Q8.5.9.8	Females	#DIV/0!
Q8.5.9.11	Transgender	#DIV/0!
Q8.5.9.14	<25	#DIV/0!
Q8.5.9.17	25+	#DIV/0!
Q8.5.9.20	Undocumented migrants	#DIV/0!
	Table B. In the past three months, have you received counselling on condom use and safe sex (for example, through an outreach service, drop-in centre or sexual health clinic)?	
Q8.5.10		
	Numerator: Number of migrants who answered "yes"	
Q8.5.10	All	
Q8.5.10.3	Males	
Q8.5.10.6	Females	
Q8.5.10.9	Transgender	
Q8.5.10.12	<25	
Q8.5.10.15	25+	
Q8.5.10.18	Undocumented migrants	
	Denominator: Number of migrants responding to the survey	
Q8.5.10.1	All	
Q8.5.10.4	Males	
Q8.5.10.7	Females	
Q8.5.10.10	Transgender	
Q8.5.10.13	<25	
Q8.5.10.16	25+	
Q8.5.10.19	Undocumented migrants	
	Percentage (%): Percentage of respondents who answered "yes" to the question "In the past three months, have you received counselling on condom use and safe sex (for example, through an outreach service, drop-in centre or sexual health clinic)?"	
Q8.5.10.2	All	#DIV/0!
Q8.5.10.5	Males	#DIV/0!
Q8.5.10.8	Females	#DIV/0!
Q8.5.10.11	Transgender	#DIV/0!
Q8.5.10.14	<25	#DIV/0!

Q8.5.10.17	25+	#DIV/0!
Q8.5.10.20	Undocumented migrants	#DIV/0!
Q8.5.11	Table C. Have you been tested for sexually transmitted infections in the past three months?	
	Numerator: Number of migrants who answered "yes" to the question "Have you been tested for sexually transmitted infections in the past three months?"	
Q8.5.11	All	
Q8.5.11.3	Males	
Q8.5.11.6	Females	
Q8.5.11.9	Transgender	
Q8.5.11.12	<25	
Q8.5.11.15	25+	
Q8.5.11.18	Undocumented migrants	
	Denominator: Number of migrants responding to the survey	
Q8.5.11.1	All	
Q8.5.11.4	Males	
Q8.5.11.7	Females	
Q8.5.11.10	Transgender	
Q8.5.11.13	<25	
Q8.5.11.16	25+	
Q8.5.11.19	Undocumented migrants	
	Percentage (%): Percentage of respondents who answered "yes" to the question "Have you been tested for sexually transmitted infections in the past three months?"	
Q8.5.11.2	All	#DIV/0!
Q8.5.11.5	Males	#DIV/0!
Q8.5.11.8	Females	#DIV/0!
Q8.5.11.11	Transgender	#DIV/0!
Q8.5.11.14	<25	#DIV/0!
Q8.5.11.17	25+	#DIV/0!
Q8.5.11.20	Undocumented migrants	#DIV/0!
Q8.5.12	Table D. Percentage of respondents who report receiving at least two of the above-mentioned HIV prevention services from a nongovernmental organization, health-care provider or other sources	
	Numerator: Number of migrants who report receiving at least two of the above-mentioned HIV prevention services from a nongovernmental organization, health-care provider or other sources	
Q8.5.12	All	
Q8.5.12.3	Males	
Q8.5.12.6	Females	
Q8.5.12.9	Transgender	
Q8.5.12.12	<25	
Q8.5.12.15	25+	
Q8.5.12.18	Undocumented migrants	
	Denominator: Number of migrants responding to the survey	
Q8.5.12.1	All	
Q8.5.12.4	Males	
Q8.5.12.7	Females	
Q8.5.12.10	Transgender	
Q8.5.12.13	<25	
Q8.5.12.16	25+	
Q8.5.12.19	Undocumented migrants	
	Percentage (%): Percentage of migrants who report receiving at least two of the above-mentioned HIV prevention services from a nongovernmental organization, health-care provider or other sources	

Q8.5.12.2	All	#DIV/0!
Q8.5.12.5	Males	#DIV/0!
Q8.5.12.8	Females	#DIV/0!
Q8.5.12.11	Transgender	#DIV/0!
Q8.5.12.14	<25	#DIV/0!
Q8.5.12.17	25+	#DIV/0!
Q8.5.12.20	Undocumented migrants	#DIV/0!
	<b>II. Programme data</b>	
	Please provide any data available, including disaggregations by provider if available. For a definition of key-population led organisations, see UNAIDS guidance here. 'Other entities' could include private for-profit and non-profit organisations which are not key-population led, including national and international nongovernmental organisations.	<a href="https://www.unaids.org/sites/default/files/media_asset/UNAIDS_GAM_Framework_2022_EN.pdf#page=35">https://www.unaids.org/sites/default/files/media_asset/UNAIDS_GAM_Framework_2022_EN.pdf#page=35</a>
Q8.5.13	<b>Proportion of migrants who are reached with HIV prevention interventions designed for migrants</b>	
	<b>Numerator: Number of migrants reached with HIV prevention interventions designed for migrants</b>	
Q8.5.13	Total	
Q8.5.13.4	Public Sector	
Q8.5.13.8	Key populations-led organization	
Q8.5.13.12	Other entities	
	<b>Denominator: Number of migrants</b>	
Q8.5.13.1	Total	
Q8.5.13.5	Public Sector	
Q8.5.13.9	Key populations-led organization	
Q8.5.13.13	Other entities	
	<b>Percentage (%): Percent of migrants who are reached with HIV prevention interventions designed for migrants</b>	
Q8.5.13.2	Total	#DIV/0!
Q8.5.13.6	Public Sector	#DIV/0!
Q8.5.13.10	Key populations-led organization	#DIV/0!
Q8.5.13.14	Other entities	#DIV/0!
	<b>Number of condoms and lubricants distributed</b>	
Q8.5.13.3	Total	
Q8.5.13.7	Number of condoms and lubricants distributed (Public sector)	
Q8.5.13.11	Number of condoms and lubricants distributed (KP-led orgs)	
Q8.5.13.15	Number of condoms and lubricants distributed (Other entities)	
	<b>III. Number of service provision sites dedicated to migrants</b>	
Q8.5.14	Total number of service provision sites	
Q.8.5.14.1	1. Sites operated by the national programme (government)	
Q.8.5.14.1	2. Sites operated by the community (civil society or nongovernmental organization)	
Q8.5.15	Number of peer outreach workers active at the time of reporting	
Q8.5.16	Number of administrative areas with service provision sites	
Q8.5.17	Total number of administrative areas in the country	
	<b>IV. Expert opinion on HIV prevention programme coverage for migrants</b>	
	If you are unable to provide survey or programme data on coverage of HIV prevention programmes for migrants, please provide responses based on expert opinion with an explanation of how you reached this answer.	

	Based on the WHO definition of universal health coverage, full coverage was defined as 'all who need the service can use it, that the service is of sufficient quality to be effective, and that use of the service will not expose the user to financial hardship'. Countries could choose from a scale of coverage, as follows: No coverage: The service is not provided; Low coverage: <30% of the population can use the effective, affordable service; Medium coverage: 30-60% of the population can use the effective, affordable service; High coverage: 61-95% of the population can use the effective, affordable service; Full coverage: 95-100% of the population can use the effective, affordable service.	
Q8.5.18	What is the estimated coverage of condom and lubricant programmes among migrants in your country?	Full coverage (95-100%)
		High coverage (61-95%)
		Medium coverage (30-60%)
		Low coverage (<30%)
		No coverage (service not provided)
Q8.5.18.1	Please explain how you reached this answer:	
Q8.5.19	What is the estimated coverage of counselling on condom use and safe sex for migrants in your country?	Full coverage (95-100%)
		High coverage (61-95%)
		Medium coverage (30-60%)
		Low coverage (<30%)
		No coverage (service not provided)
Q8.5.19.1	Please explain how you reached this answer:	
Q8.5.20	What is the estimated coverage of STI testing for migrants in your country?	Full coverage (95-100%)
		High coverage (61-95%)
		Medium coverage (30-60%)
		Low coverage (<30%)
		No coverage (service not provided)
Q8.5.20.1	Please explain how you reached this answer:	
Q8.5.21	What is the estimated coverage of condom and lubricant programmes among undocumented migrants in your country?	Full coverage (95-100%)
		High coverage (61-95%)
		Medium coverage (30-60%)
		Low coverage (<30%)
		No coverage (service not provided)
Q8.5.21.1	Please explain how you reached this answer:	
Q8.5.22	What is the estimated coverage of counselling on condom use and safe sex for undocumented migrants in your country?	Full coverage (95-100%)
		High coverage (61-95%)
		Medium coverage (30-60%)
		Low coverage (<30%)
		No coverage (service not provided)
Q8.5.22.1	Please explain how you reached this answer:	
Q8.5.23	What is the estimated coverage of STI testing for undocumented migrants in your country?	Full coverage (95-100%)
		High coverage (61-95%)

		Medium coverage (30-60%)
		Low coverage (<30%)
		No coverage (service not provided)
Q8.5.23.1	Please explain how you reached this answer:	

Coverage of HIV prevention programmes among sex workers

This form is pre-populated with data reported in the previous data collection round. Previously entered data is shown below each data entry field. Please enter new data if available. If no new data are available, please review and enter the data from the previous dataset in the data entry field.

DDM 2024	Question	Response
	This indicator is aligned with GAM 1.6A. Guidance on responding to this question is available here.	<a href="https://www.unaids.org/sites/default/files/media_asset/global-aids-monitoring_en.pdf#page=26">https://www.unaids.org/sites/default/files/media_asset/global-aids-monitoring_en.pdf#page=26</a>
Q8.6	Are data available?	Yes
		No
Q8.6.1	What type of data are available? Please select all that apply:	Behavioural Surveillance Survey
	Note: If you have survey and/or programme data, this is preferred to expert opinion.	Special study or other survey
		Programme data
		Expert opinion
8.6.1.1		Other
	Please specify sampling strategy and location:	
Q8.6.2	Data Collection Period From:	
Q8.6.3	Data Collection Period To:	
Q8.6.4	Additional information related to entered data. e.g. reference to primary data source, methodological concerns:	
Q8.6.4.1	If available, upload a relevant supporting document by clicking on the icon. Any file format is acceptable, but it must be less than 8MB in size. When it has uploaded successfully, a unique ID will appear in the box.	
Q8.6.5	Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source:	
	I. Behavioural surveillance or other special surveys	
Q8.6.6	Please specify sampling strategy and location:	
Q8.6.7	Sample size - Number of Survey Respondents	
Q8.6.8	For which survey questions are you able to provide data on sex workers? Please select all that apply:	In the past three months, have you been given condoms and lubricant (for example, through an outreach service, drop-in centre or sexual health clinic)?
		In the past three months, have you received counselling on condom use and safe sex (for example, through an outreach service, drop-in centre or sexual health clinic)?
		Have you been tested for sexually transmitted infections in the past three months?
		Percentage of respondents who report receiving at least two of the above-mentioned HIV prevention services from a nongovernmental organization, health-care provider or other sources

	Please provide any data available, including disaggregations by age, sex and transgender if available.	
Q8.6.9	Table A. In the past three months, have you been given condoms and lubricant (for example, through an outreach service, drop-in centre or sexual health clinic)?	
	Numerator: Number of sex workers who answered "yes"	
Q8.6.9	All	
Q8.6.9.3	Males	
Q8.6.9.6	Females	
Q8.6.9.9	Transgender	
Q8.6.9.12	<25	
Q8.6.9.15	25+	
	Denominator: Number of sex workers responding to the survey	
Q8.6.9.1	All	
Q8.6.9.4	Males	
Q8.6.9.7	Females	
Q8.6.9.10	Transgender	
Q8.6.9.13	<25	
Q8.6.9.16	25+	
	Percentage (%): Percentage of respondents who answered "yes" to the question "In the past three months, have you been given condoms and lubricant (for example, through an outreach service, drop-in centre or sexual health clinic)?"	
Q8.6.9.2	All	#DIV/0!
Q8.6.9.5	Males	#DIV/0!
Q8.6.9.8	Females	#DIV/0!
Q8.6.9.11	Transgender	#DIV/0!
Q8.6.9.14	<25	#DIV/0!
Q8.6.9.17	25+	#DIV/0!
Q8.6.10	Table B. In the past three months, have you received counselling on condom use and safe sex (for example, through an outreach service, drop-in centre or sexual health clinic)?	
	Numerator: Number of sex workers who answered "yes"	
Q8.6.10	All	
Q8.6.10.3	Males	
Q8.6.10.6	Females	
Q8.6.10.9	Transgender	
Q8.6.10.12	<25	
Q8.6.10.15	25+	
	Denominator: Number of sex workers responding to the survey	
Q8.6.10.1	All	
Q8.6.10.4	Males	
Q8.6.10.7	Females	
Q8.6.10.10	Transgender	
Q8.6.10.13	<25	
Q8.6.10.16	25+	
	Percentage (%): Percentage of respondents who answered "yes" to the question "In the past three months, have you received counselling on condom use and safe sex (for example, through an outreach service, drop-in centre or sexual health clinic)?"	
Q8.6.10.2	All	#DIV/0!
Q8.6.10.5	Males	#DIV/0!
Q8.6.10.8	Females	#DIV/0!
Q8.6.10.11	Transgender	#DIV/0!
Q8.6.10.14	<25	#DIV/0!

Q8.6.10.17	25+	#DIV/0!
Q8.6.11	Table C. Have you been tested for sexually transmitted infections in the past three months?	
	Numerator: Number of sex workers who answered "yes" to the question "Have you been tested for sexually transmitted infections in the past three months?"	
Q8.6.11	All	
Q8.6.11.3	Males	
Q8.6.11.6	Females	
Q8.6.11.9	Transgender	
Q8.6.11.12	<25	
Q8.6.11.15	25+	
	Denominator: Number of sex workers responding to the survey	
Q8.6.11.1	All	
Q8.6.11.4	Males	
Q8.6.11.7	Females	
Q8.6.11.10	Transgender	
Q8.6.11.13	<25	
Q8.6.11.16	25+	
	Percentage (%): Percentage of respondents who answered "yes" to the question "Have you been tested for sexually transmitted infections in the past three months?"	
Q8.6.11.2	All	#DIV/0!
Q8.6.11.5	Males	#DIV/0!
Q8.6.11.8	Females	#DIV/0!
Q8.6.11.11	Transgender	#DIV/0!
Q8.6.11.14	<25	#DIV/0!
Q8.6.11.17	25+	#DIV/0!
Q8.6.12	Table D. Percentage of respondents who report receiving at least two of the above-mentioned HIV prevention services from a nongovernmental organization, health-care provider or other sources	
	Numerator: Number of sex workers who report receiving at least two of the above-mentioned HIV prevention services from a nongovernmental organization, health-care provider or other sources	
Q8.6.12	All	
Q8.6.12.3	Males	
Q8.6.12.6	Females	
Q8.6.12.9	Transgender	
Q8.6.12.12	<25	
Q8.6.12.15	25+	
	Denominator: Number of sex workers responding to the survey	
Q8.6.12.1	All	
Q8.6.12.4	Males	
Q8.6.12.7	Females	
Q8.6.12.10	Transgender	
Q8.6.12.13	<25	
Q8.6.12.16	25+	
	Percentage (%): Percentage of sex workers who report receiving at least two of the above-mentioned HIV prevention services from a nongovernmental organization, health-care provider or other sources	
Q8.6.12.2	All	#DIV/0!
Q8.6.12.5	Males	#DIV/0!
Q8.6.12.8	Females	#DIV/0!
Q8.6.12.11	Transgender	#DIV/0!
Q8.6.12.14	<25	#DIV/0!
Q8.6.12.17	25+	#DIV/0!



	<b>II. Programme data</b>	
	Please provide any data available, including disaggregations by provider if available. For a definition of key-population led organisations, see UNAIDS guidance here. 'Other entities' could include private for-profit and non-profit organisations which are not key-population led, including national and international nongovernmental organisations.	<a href="https://www.unaids.org/sites/default/files/media_asset/global-aids-monitoring_en.pdf#page=34">https://www.unaids.org/sites/default/files/media_asset/global-aids-monitoring_en.pdf#page=34</a>
Q8.6.13	<b>Proportion of sex workers who are reached with HIV prevention interventions designed for sex workers</b>	
	<b>Numerator: Number of sex workers reached with HIV prevention interventions designed for sex workers</b>	
Q8.6.13	Total	
Q8.6.13.4	Public Sector	
Q8.6.13.8	Key populations-led organization	
Q8.6.13.12	Other entities	
	<b>Denominator: Number of sex workers</b>	
Q8.6.13.1	Total	
Q8.6.13.5	Public Sector	
Q8.6.13.9	Key populations-led organization	
Q8.6.13.13	Other entities	
	<b>Percentage (%): Percent of sex workers who are reached with HIV prevention interventions designed for sex workers</b>	
Q8.6.13.2	Total	#DIV/0!
Q8.6.13.6	Public Sector	#DIV/0!
Q8.6.13.10	Key populations-led organization	#DIV/0!
Q8.6.13.14	Other entities	#DIV/0!
	<b>Number of condoms and lubricants distributed</b>	
Q8.6.13.3	Total	
Q8.6.13.7	Number of condoms and lubricants distributed (Public sector)	
Q8.6.13.11	Number of condoms and lubricants distributed (KP-led orgs)	
Q8.6.13.15	Number of condoms and lubricants distributed (Other entities)	
	<b>III. Number of service provision sites dedicated to sex workers</b>	
Q8.6.14	Total number of service provision sites	
Q8.6.14.1	1. Sites operated by the national programme (government)	
Q8.6.14.2	2. Sites operated by the community (civil society or nongovernmental organization)	
Q8.6.15	Number of peer outreach workers active at the time of reporting	
Q8.6.16	Number of administrative areas with service provision sites	
Q8.6.17	Total number of administrative areas in the country	
	<b>IV. Expert opinion on HIV prevention programme coverage for sex workers</b>	
	If you are unable to provide survey or programme data on coverage of HIV prevention programmes for sex workers, please provide responses based on expert opinion with an explanation of how you reached this answer.	
	Based on the WHO definition of universal health coverage, full coverage was defined as 'all who need the service can use it, that the service is of sufficient quality to be effective, and that use of the service will not expose the user to financial hardship'. Countries could choose from a scale of coverage, as follows: No coverage: The service is not provided; Low coverage: <30% of the population can use the effective, affordable service; Medium coverage: 30-60% of the population can use the effective, affordable service; High coverage: 61-95% of the population can use the effective, affordable service; Full coverage: 95-100% of the population can use the effective, affordable service.	
Q8.6.18	What is the estimated coverage of condom and lubricant programmes among sex workers in your country?	Full coverage (95-100%)
		High coverage (61-95%)
		Medium coverage (30-60%)
		Low coverage (<30%)

		No coverage (service not provided)
Q8.6.18.1	Please explain how you reached this answer:	
Q8.6.19	What is the estimated coverage of counselling on condom use and safe sex for sex workers in your country?	Full coverage (95-100%)
		High coverage (61-95%)
		Medium coverage (30-60%)
		Low coverage (<30%)
		No coverage (service not provided)
Q8.6.19.1	Please explain how you reached this answer:	
Q8.6.20	What is the estimated coverage of STI testing for sex workers in your country?	Full coverage (95-100%)
		High coverage (61-95%)
		Medium coverage (30-60%)
		Low coverage (<30%)
		No coverage (service not provided)
Q8.6.20.1	Please explain how you reached this answer:	

Coverage of HIV prevention programmes among transgender people		
	This form is pre-populated with data reported in the previous data collection round. Previously entered data is shown below each data entry field. Please enter new data if available. If no new data are available, please review and enter the data from the previous dataset in the data entry field.	
DDM 2024	Question	Response
	This indicator is aligned with GAM 1.6D. Guidance on responding to this question is available here.	<a href="https://www.unaids.org/sites/default/files/media_asset/global-aids-monitoring_en.pdf#page=26">https://www.unaids.org/sites/default/files/media_asset/global-aids-monitoring_en.pdf#page=26</a>
8.7	Are data available?	Yes
		No
8.7.1	What type of data are available? Please select all that apply:	Behavioural Surveillance Survey
	Note: If you have survey and/or programme data, this is preferred to expert opinion.	Special study or other survey
		Programme data
		Expert opinion
8.7.1.1		Other
	Please specify sampling strategy and location:	
8.7.2	Data Collection Period From:	
8.7.3	Data Collection Period To:	
8.7.4	Additional information related to entered data. e.g. reference to primary data source, methodological concerns:	
8.7.4.1	If available, upload a relevant supporting document by clicking on the icon. Any file format is acceptable, but it must be less than 8MB in size. When it has uploaded successfully, a unique ID will appear in the box.	
8.7.5	Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source:	
	I. Behavioural surveillance or other special surveys	
8.7.6	Please specify sampling strategy and location:	
8.7.7	Sample size - Number of Survey Respondents	
8.7.8	For which survey questions are you able to provide data on transgender people? Please select all that apply:	In the past three months, have you been given condoms and lubricant (for example, through an outreach service, drop-in centre or sexual health clinic)?
		In the past three months, have you received counselling on condom use and safe sex (for example, through an outreach service, drop-in centre or sexual health clinic)?
		Have you been tested for sexually transmitted infections in the past three months?
		Percentage of respondents who report receiving at least two of the above-mentioned HIV prevention services from a nongovernmental organization, health-care provider or other sources
	Please provide any data available, including disaggregations by age, sex and transgender if available.	
8.7.9	Table A. In the past three months, have you been given condoms and lubricant (for example, through an outreach service, drop-in centre or sexual health clinic)?	
	Numerator: Number of transgender people who answered "yes"	

Q8.7.9	All	
Q8.7.9.3	Transman	
Q8.7.9.6	Transwoman	
Q8.7.9.9	Other	
Q8.7.9.12	<25	
Q8.7.9.15	25+	
	Denominator: Number of transgender people responding to the survey	
Q8.7.9.1	All	
Q8.7.9.4	Transman	
Q8.7.9.7	Transwoman	
Q8.7.9.10	Other	
Q8.7.9.13	<25	
Q8.7.9.16	25+	
	Percentage (%): Percentage of respondents who answered "yes" to the question "In the past three months, have you been given condoms and lubricant (for example, through an outreach service, drop-in centre or sexual health clinic)?"	
Q8.7.9.2	All	#DIV/0!
Q8.7.9.5	Transman	#DIV/0!
Q8.7.9.8	Transwoman	#DIV/0!
Q8.7.9.11	Other	#DIV/0!
Q8.7.9.14	<25	#DIV/0!
Q8.7.9.17	25+	#DIV/0!
8.7.10	Table B. In the past three months, have you received counselling on condom use and safe sex (for example, through an outreach service, drop-in centre or sexual health clinic)?	
	Numerator: Number of transgender people who answered "yes"	
Q8.7.10	All	
Q8.7.10.3	Transman	
Q8.7.10.6	Transwoman	
Q8.7.10.9	Other	
Q8.7.10.12	<25	
Q8.7.10.15	25+	
	Denominator: Number of transgender people responding to the survey	
Q8.7.10.1	All	
Q8.7.10.4	Transman	
Q8.7.10.7	Transwoman	
Q8.7.10.10	Other	
Q8.7.10.13	<25	
Q8.7.10.16	25+	
	Percentage (%): Percentage of respondents who answered "yes" to the question "In the past three months, have you received counselling on condom use and safe sex (for example, through an outreach service, drop-in centre or sexual health clinic)?"	
Q8.7.10.2	All	#DIV/0!
Q8.7.10.5	Transman	#DIV/0!
Q8.7.10.8	Transwoman	#DIV/0!
Q8.7.10.11	Other	#DIV/0!
Q8.7.10.14	<25	#DIV/0!
Q8.7.10.17	25+	#DIV/0!
8.7.11	Table C. Have you been tested for sexually transmitted infections in the past three months?	
	Numerator: Number of transgender people who answered "yes" to the question "Have you been tested for sexually transmitted infections in the past three months?"	

Q8.7.11	All	
Q8.7.11.3	Transman	
Q8.7.11.6	Transwoman	
Q8.7.11.9	Other	
Q8.7.11.12	<25	
Q8.7.11.15	25+	
	Denominator: Number of transgender people responding to the survey	
Q8.7.11.1	All	
Q8.7.11.4	Transman	
Q8.7.11.7	Transwoman	
Q8.7.11.10	Other	
Q8.7.11.13	<25	
Q8.7.11.16	25+	
	Percentage (%): Percentage of respondents who answered "yes" to the question "Have you been tested for sexually transmitted infections in the past three months?"	
Q8.7.11.2	All	#DIV/0!
Q8.7.11.5	Transman	#DIV/0!
Q8.7.11.8	Transwoman	#DIV/0!
Q8.7.11.11	Other	#DIV/0!
Q8.7.11.14	<25	#DIV/0!
Q8.7.11.17	25+	#DIV/0!
8.7.12	Table D. Percentage of respondents who report receiving at least two of the above-mentioned HIV prevention services from a nongovernmental organization, health-care provider or other sources	
	Numerator: Number of transgender people who report receiving at least two of the above-mentioned HIV prevention services from a nongovernmental organization, health-care provider or other sources	
Q8.7.12	All	
Q8.7.12.3	Transman	
Q8.7.12.6	Transwoman	
Q8.7.12.9	Other	
Q8.7.12.12	<25	
Q8.7.12.15	25+	
	Denominator: Number of transgender people responding to the survey	
Q8.7.12.1	All	
Q8.7.12.4	Transman	
Q8.7.12.7	Transwoman	
Q8.7.12.10	Other	
Q8.7.12.13	<25	
Q8.7.12.16	25+	
	Percentage (%): Percentage of transgender people who report receiving at least two of the above-mentioned HIV prevention services from a nongovernmental organization, health-care provider or other sources	
Q8.7.12.2	All	#DIV/0!
Q8.7.12.5	Transman	#DIV/0!
Q8.7.12.8	Transwoman	#DIV/0!
Q8.7.12.11	Other	#DIV/0!
Q8.7.12.14	<25	#DIV/0!
Q8.7.12.17	25+	#DIV/0!
	II. Programme data	

	Please provide any data available, including disaggregations by provider if available. For a definition of key-population led organisations, see UNAIDS guidance here. 'Other entities' could include private for-profit and non-profit organisations which are not key-population led, including national and international nongovernmental organisations.	<a href="https://www.unaids.org/sites/default/files/media_asset/global-aids-monitoring_en.pdf#page=34">https://www.unaids.org/sites/default/files/media_asset/global-aids-monitoring_en.pdf#page=34</a>
8.7.13	<b>Proportion of transgender people who are reached with HIV prevention interventions designed for transgender people</b>	
	<b>Numerator: Number of transgender people reached with HIV prevention interventions designed for transgender people</b>	
Q8.7.13	Total	
Q8.7.13.3	Public Sector	
Q8.7.13.6	Key populations-led organization	
Q8.7.13.9	Other entities	
	<b>Denominator: Number of transgender people</b>	
Q8.7.13.1	Total	
Q8.7.13.4	Public Sector	
Q8.7.13.7	Key populations-led organization	
Q8.7.13.10	Other entities	
	<b>Percentage (%): Percent of transgender people who are reached with HIV prevention interventions designed for transgender people</b>	
Q8.7.13.2	Total	#DIV/0!
Q8.7.13.5	Public Sector	#DIV/0!
Q8.7.13.8	Key populations-led organization	#DIV/0!
Q8.7.13.11	Other entities	#DIV/0!
	<b>III. Number of service provision sites dedicated to transgender people</b>	
8.7.14	Total number of service provision sites	
Q8.7.14.1	1. Sites operated by the national programme (government)	
Q8.7.14.2	2. Sites operated by the community (civil society or nongovernmental organization)	
8.7.15	Number of peer outreach workers active at the time of reporting	
8.7.16	Number of administrative areas with service provision sites	
8.7.17	Total number of administrative areas in the country	
	<b>IV. Expert opinion on HIV prevention programme coverage for transgender people</b>	
	If you are unable to provide survey or programme data on coverage of HIV prevention programmes for transgender people, please provide responses based on expert opinion with an explanation of how you reached this answer.	
	Based on the WHO definition of universal health coverage, full coverage was defined as 'all who need the service can use it, that the service is of sufficient quality to be effective, and that use of the service will not expose the user to financial hardship'. Countries could choose from a scale of coverage, as follows: No coverage: The service is not provided; Low coverage: <30% of the population can use the effective, affordable service; Medium coverage: 30-60% of the population can use the effective, affordable service; High coverage: 61-95% of the population can use the effective, affordable service; Full coverage: 95-100% of the population can use the effective, affordable service.	
8.7.18	What is the estimated coverage of condom and lubricant programmes among transgender people in your country?	Full coverage (95-100%)
		High coverage (61-95%)
		Medium coverage (30-60%)
		Low coverage (<30%)
		No coverage (service not provided)
8.7.18.1	Please explain how you reached this answer:	

8.7.19	What is the estimated coverage of counselling on condom use and safe sex for transgender people in your country?	Full coverage (95-100%)
		High coverage (61-95%)
		Medium coverage (30-60%)
		Low coverage (<30%)
		No coverage (service not provided)
8.7.19.1	Please explain how you reached this answer:	
8.7.20	What is the estimated coverage of STI testing for transgender people in your country?	Full coverage (95-100%)
		High coverage (61-95%)
		Medium coverage (30-60%)
		Low coverage (<30%)
		No coverage (service not provided)
8.7.20.1	Please explain how you reached this answer:	

Coverage of HIV prevention programmes in prisons

This form is pre-populated with data reported in the previous data collection round. Previously entered data is shown below each data entry field. Please enter new data if available. If no new data are available, please review and enter the data from the previous dataset in the data entry field.

DDM 2024	Question	Response
	This indicator is aligned with GAM 1.7. Guidance on responding to this question is available here.	<a href="https://www.unaids.org/sites/default/files/media_asset/global-aids-monitoring_en.pdf#page=28">https://www.unaids.org/sites/default/files/media_asset/global-aids-monitoring_en.pdf#page=28</a>
8.8	Are data available?	Yes
		No
Q8.8.1	Data measurement tool / source	Routine programme data
		Other (please specify)
Q8.8.1.1	Other measurement tool / source	
Q8.8.2	Data Collection Period From:	
Q8.8.3	Data Collection Period To:	
Q8.8.4	Additional information related to entered data. e.g. reference to primary data source, methodological concerns:	
Q8.8.4.1	If available, upload a relevant supporting document by clicking on the icon. Any file format is acceptable, but it must be less than 8MB in size. When it has uploaded successfully, a unique ID will appear in the box.	
Q8.8.5	Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source:	
Q8.8.6	Number of clean needles distributed to prisoners	
Q8.8.6.1	Number of prisoners receiving opioid substitution therapy	
Q8.8.6.2	Number of condoms distributed to prisoners	
Q8.8.6.3	Number of prisoners receiving antiretroviral therapy	
Q8.8.6.4	Number of prisoners tested for HIV	
Q8.8.7	People living with HIV among prisoners	
Q8.8.7	Numerator: Number of people living with HIV among prisoners	
Q8.8.7.1	Percentage (%): Percentage of people living with HIV among prisoners	
Q8.8.8	Prisoners with hepatitis B only	
Q8.8.8	Numerator: Number of prisoners with hepatitis B	
Q8.8.8.1	Percentage (%): Percentage of prisoners with hepatitis B	
Q8.8.9	Prisoners co-infected with HIV and hepatitis B virus	
Q8.8.9	Numerator: Number of prisoners co-infected with HIV and hepatitis B virus	
Q8.8.9.1	Percentage (%): Percentage of prisoners co-infected with HIV and hepatitis B virus	
Q8.8.10	Prisoners with hepatitis C only	
Q8.8.10	Numerator: Number of prisoners with hepatitis C	
Q8.8.10.1	Percentage (%): Percentage of prisoners with hepatitis C	
Q8.8.11	Prisoners co-infected with HIV and hepatitis C virus	
Q8.8.11	Numerator: Number of prisoners co-infected with HIV and hepatitis C virus	
Q8.8.11.1	Percentage (%): Percentage of prisoners co-infected with HIV and hepatitis C virus	
Q8.8.12	Prisoners co-infected with HIV and TB	
Q8.8.12	Numerator: Number of prisoners co-infected with HIV and TB	
Q8.8.12.1	Percentage (%): Percentage of prisoners co-infected with HIV and TB	



Condom use among men who have sex with men

This form is pre-populated with data reported in the previous data collection round. Previously entered data is shown below each data entry field. Please enter new data if available. If no new data are available, please review and enter the data from the previous dataset in the data entry field.

DDM 2024	Question	Response
9.1.0	Does your country collect data on condom use among MSM?	Yes
		No
9.1.0.1	If no, please scroll to the bottom of this form, select form status as 'Complete' and click on 'Save & Exit Form'.	
	Men who have sex with men	
	This indicator is aligned with GAM 1.5B. Guidance on responding to this question is available here.	<a href="https://www.unaids.org/sites/default/files/media_asset/global-aids-monitoring_en.pdf#page=20">https://www.unaids.org/sites/default/files/media_asset/global-aids-monitoring_en.pdf#page=20</a>
Q9.1.1	Data measurement tool / source	Behavioural Surveillance Survey
		Special Study
Q9.1.1.1		Other
Q9.1.2	Please specify sampling strategy and location:	
Q9.1.3	Data Collection Period From:	
Q9.1.4	Data Collection Period To:	
Q9.1.5	Were participants asked about the following?*	
Q9.1.5	Use of PrEP to prevent HIV transmission	Yes
		No
		Don't know
Q9.1.5.1	Use of Treatment as Prevention to prevent HIV transmission	Yes
		No
		Don't know
	*As PrEP and using Treatment as Prevention are having an effect on HIV risk historically associated with condomless sex, it is useful to know if survey participants are using PrEP or TasP to prevent HIV transmission to themselves or their sexual partners during condomless sex. Condom use is still important to reduce transmission of STIs, and HIV where PrEP or TasP are not used.	
Q9.1.6	Additional information related to entered data. e.g. reference to primary data source, methodological concerns:	
Q9.1.6.1	If available, upload a relevant supporting document by clicking on the icon. Any standard file format is acceptable, but it must be less than 10MB in size. When it has uploaded successfully, a unique ID will appear in the box.	
Q9.1.7	Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source:	
Q9.1.8	Sample size - Number of Survey Respondents	
Q9.1.9		
	Numerator: Number of men who have sex with men who reported using a condom the last time they had anal sex	
Q9.1.9	All	
Q9.1.9.3	<25	
Q9.1.9.6	25+	
	Denominator: Number of men who have sex with men who reported having had anal sex with a male partner in the past six months	
Q9.1.9.1	All	
Q9.1.9.4	<25	

Q9.1.9.7	25+	
	Percentage (%): Percentage of men reporting using a condom the last time they had anal sex with a male partner	
Q9.1.9.2	All	#DIV/0!
Q9.1.9.5	<25	#DIV/0!
Q9.1.9.8	25+	#DIV/0!

Condom use among people who inject drugs

This form is pre-populated with data reported in the previous data collection round. Previously entered data is shown below each data entry field. Please enter new data if available. If no new data are available, please review and enter the data from the previous dataset in the data entry field.

DDM 2024	Question	Response
	People who inject drugs	
9.2.0	Does your country collect data on condom use among people who inject drugs?	Yes
		No
9.2.0.1	If no, please scroll to the bottom of this form, select form status as 'Complete' and click on 'Save & Exit Form'.	
	This indicator is aligned with GAM 1.5C. Guidance on responding to this question is available here.	<a href="https://www.unaids.org/sites/default/files/media_asset/global-aids-monitoring_en.pdf#page=22">https://www.unaids.org/sites/default/files/media_asset/global-aids-monitoring_en.pdf#page=22</a>
Q9.2.1	Data measurement tool / source	Behavioural Surveillance Survey
		Special Study
		Other
Q9.2.1.1	Other measurement tool / source	
Q9.2.2	Please specify sampling strategy and location:	
Q9.2.3	Data Collection Period From:	
Q9.2.4	Data Collection Period To:	
Q9.2.5	Additional information related to entered data. e.g. reference to primary data source, methodological concerns:	
Q9.2.5.1	If available, upload a relevant supporting document by clicking on the icon. Any standard file format is acceptable, but it must be less than 8MB in size. When it has uploaded successfully, a unique ID will appear in the box.	
Q9.2.6	Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source:	
Q9.2.7	Sample size - Number of Survey Respondents	
	Numerator: Number of people who inject drugs who reported using a condom the last time they had sex	
Q9.2.8	All	
Q9.2.8.3	Males	
Q9.2.8.6	Females	
Q9.2.8.9	Transgender	
Q9.2.8.12	<25	
Q9.2.8.15	25+	
	Denominator: Number of people who inject drugs who report having injected drugs and having had sexual intercourse in the past month	
Q9.2.8.1	All	
Q9.2.8.4	Males	
Q9.2.8.7	Females	
Q9.2.8.10	Transgender	
Q9.2.8.13	<25	
Q9.2.8.16	25+	
	Percentage (%): Percentage of people who inject drugs reporting using a condom the last time they had sexual intercourse	
Q9.2.8.2	All	#DIV/0!
Q9.2.8.5	Males	#DIV/0!
Q9.2.8.8	Females	#DIV/0!
Q9.2.8.11	Transgender	#DIV/0!

Q9.2.8.14	<25	#DIV/0!
Q9.2.8.17	25+	#DIV/0!

CONDOM USE AMONG MIGRANTS (PERSONS BORN ABROAD)

This form is pre-populated with data reported in the previous data collection round. Previously entered data is shown below each data entry field. Please enter new data if available. If no new data are available, please review and enter the data from the previous dataset in the data entry field.

DDM 2024	Question	Response
	Migrants (persons born abroad)	
9.3.0	Does your country collect data on condom use among migrants (people born abroad)?	Yes
		No
9.3.0.1	If no, please scroll to the bottom of this form, select form status as 'Complete' and click on 'Save & Exit Form'.	
Q9.3.1	Data measurement tool / source	Behavioural Surveillance Survey
		Special Study
		Other
Q9.3.1.1	Other measurement tool / source	
Q9.3.2	Please specify sampling strategy and location:	
Q9.3.3	Data Collection Period From:	
Q9.3.4	Data Collection Period To:	
Q9.3.5	Were participants asked about the following?*	
Q9.3.5	Use of PrEP to prevent HIV transmission	Yes
		No
		Don't know
Q9.3.5.1	Use of Treatment as Prevention to prevent HIV transmission	Yes
		No
		Don't know
	*As PrEP and using Treatment as Prevention are having an effect on HIV risk historically associated with condomless sex, it is useful to know if survey participants are using PrEP or TasP to prevent HIV transmission to themselves or their sexual partners during condomless sex. Condom use is still important to reduce transmission of STIs, and HIV where PrEP or TasP are not used.	
Q9.3.6	Additional information related to entered data. e.g. reference to primary data source, methodological concerns:	
Q9.3.6.1	If available, upload a relevant supporting document by clicking on the icon. Any standard file format is acceptable, but it must be less than 8MB in size. When it has uploaded successfully, a unique ID will appear in the box.	
Q9.3.7	Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source:	
Q9.3.8	Sample size - Number of Survey Respondents	
Q9.3.9		
	Numerator: Number of migrants who reported using a condom the last time they had sex	
Q9.3.9	All	
Q9.3.9.3	Males	
Q9.3.9.6	Females	
Q9.3.9.9	Transgender	
Q9.3.9.12	<25	
Q9.3.9.15	25+	
Q9.3.9.18	Undocumented migrants	
	Denominator: Number of migrants who report having had sexual intercourse in the past six months	
Q9.3.9.1	All	
Q9.3.9.4	Males	

Q9.3.9.7	Females	
Q9.3.9.10	Transgender	
Q9.3.9.13	<25	
Q9.3.9.16	25+	
Q9.3.9.19	Undocumented migrants	
	Percentage (%): Percentage of migrants reporting using a condom the last time they had sexual intercourse	
Q9.3.9.2	All	#DIV/0!
Q9.3.9.5	Males	#DIV/0!
Q9.3.9.8	Females	#DIV/0!
Q9.3.9.11	Transgender	#DIV/0!
Q9.3.9.14	<25	#DIV/0!
Q9.3.9.17	25+	#DIV/0!
Q9.3.9.20	Undocumented migrants	#DIV/0!

CONDOM USE AMONG SEX WORKERS

This form is pre-populated with data reported in the previous data collection round. Previously entered data is shown below each data entry field. Please enter new data if available. If no new data are available, please review and enter the data from the previous dataset in the data entry field.

DDM 2024	Question	Response
	Sex workers	
9.4.0	Does your country collect data on condom use among sex workers?	Yes
		No
9.4.0.1	If no, please scroll to the bottom of this form, select form status as 'Complete' and click on 'Save & Exit Form'.	
	This indicator is aligned with GAM 1.5A. Guidance on responding to this question is available here.	<a href="https://www.unaids.org/sites/default/files/media_asset/global-aids-monitoring_en.pdf#page=18">https://www.unaids.org/sites/default/files/media_asset/global-aids-monitoring_en.pdf#page=18</a>
9.4.1	Data measurement tool / source	Behavioural Surveillance Survey
		Special Study
		Other
9.4.1.1	Other measurement tool / source	
9.4.2	Please specify sampling strategy and location:	
9.4.3	Data Collection Period From:	
9.4.4	Data Collection Period To:	
9.4.5	Were participants asked about the following?*	
	Use of PrEP to prevent HIV transmission	Yes
		No
		Don't know
9.4.5.1	Use of Treatment as Prevention to prevent HIV transmission	Yes
		No
		Don't know
	*As PrEP and using Treatment as Prevention are having an effect on HIV risk historically associated with condomless sex, it is useful to know if survey participants are using PrEP or TasP to prevent HIV transmission to themselves or their sexual partners during condomless sex. Condom use is still important to reduce transmission of STIs, and HIV where PrEP or TasP are not used.	
9.4.6	Additional information related to entered data. e.g. reference to primary data source, methodological concerns:	
9.4.6.1	If available, upload a relevant supporting document by clicking on the icon. Any standard file format is acceptable, but it must be less than 8MB in size. When it has uploaded successfully, a unique ID will appear in the box.	
9.4.7	Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source:	
9.4.8	Sample size - Number of Survey Respondents	
9.4.9	Numerator: Number of sex workers who reported using a condom with their last client	
9.4.9	All	
9.4.9.3	Males	
9.4.9.6	Females	
9.4.9.9	Transgender	
9.4.9.12	<25	
9.4.9.15	25+	
	Denominator: Number of sex workers who reported having commercial sex in the past 12 months	
9.4.9.1	All	

9.4.9.4	Males	
9.4.9.7	Females	
9.4.9.10	Transgender	
9.4.9.13	<25	
9.4.9.16	25+	
	Percentage (%): Percentage of sex workers reporting using a condom with their most recent client	
9.4.9.2	All	#DIV/0!
9.4.9.5	Males	#DIV/0!
9.4.9.8	Females	#DIV/0!
9.4.9.11	Transgender	#DIV/0!
9.4.9.14	<25	#DIV/0!
9.4.9.17	25+	#DIV/0!
9.6	Any further comments?	



CONDOM USE AMONG TRANSGENDER PEOPLE

This form is pre-populated with data reported in the previous data collection round. Previously entered data is shown below each data entry field. Please enter new data if available. If no new data are available, please review and enter the data from the previous dataset in the data entry field.

DDM 202	Question	Response
	Transgender people	
9.5.0	Does your country collect data on condom use among transgender people?	Yes
		No
9.5.0.1	If no, please scroll to the bottom of this form, select form status as 'Complete' and click on 'Save & Exit Form'.	
	This indicator is aligned with GAM 1.5D. Guidance on responding to this question is available here.	<a href="https://www.unaids.org/sites/default/files/media_asset/global-aids-monitoring_en.pdf#page=24">https://www.unaids.org/sites/default/files/media_asset/global-aids-monitoring_en.pdf#page=24</a>
Q9.5.1	Data measurement tool / source	Behavioural Surveillance Survey
		Special Study
		Other
Q9.5.1.1	Other measurement tool / source	
Q9.5.2	Please specify sampling strategy and location:	
Q9.5.3	Data Collection Period From:	
Q9.5.4	Data Collection Period To:	
Q9.5.5	Were participants asked about the following?*	
	Use of PrEP to prevent HIV transmission	Yes
		No
		Don't know
Q9.5.5.1	Use of Treatment as Prevention to prevent HIV transmission	Yes
		No
		Don't know
Q9.5.6	Additional information related to entered data. e.g. reference to primary data source, methodological concerns:	
Q9.5.6.1	If available, upload a relevant supporting document by clicking on the icon. Any standard file format is acceptable, but it must be less than 10MB in size. When it has uploaded successfully, a unique ID will appear in the box.	
Q9.5.7	Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source:	
Q9.5.8	Sample size - Number of Survey Respondents	
Q9.5.9	Numerator: Number of transgender people who reported using a condom at last sexual intercourse or anal sex	
Q9.5.9	All	
Q9.5.9.3	Transman	
Q9.5.9.6	Transwoman	
Q9.5.9.9	Other	
Q9.5.9.12	<25	
Q9.5.9.15	25+	
	Denominator: Number of transgender people surveyed who reported having sexual intercourse or anal sex in the past six months	
Q9.5.9.1	All	
Q9.5.9.4	Transman	

Q9.5.9.7	Transwoman	
Q9.5.9.10	Other	
Q9.5.9.13	<25	
Q9.5.9.16	25+	
	Percentage (%): Percentage of transgender people reporting using a condom during their most recent sexual intercourse or anal sex	
Q9.5.9.2	All	#DIV/0!
Q9.5.9.5	Transman	#DIV/0!
Q9.5.9.8	Transwoman	#DIV/0!
Q9.5.9.11	Other	#DIV/0!
Q9.5.9.14	<25	#DIV/0!
Q9.5.9.17	25+	#DIV/0!
9.6	Any further comments?	

**HARM REDUCTION POLICY FOR PEOPLE WHO INJECT DRUGS**

This form is pre-populated with data reported in the previous data collection round. Previously entered data is shown below each data entry field. Please enter new data if available. If no new data are available, please review and enter the data from the previous dataset in the data entry field.

DDM 2024	Question	Response
10.1	Are needle and syringe programmes operational in your country?	Yes
		No
10.1.1	Are needle and syringe programmes operational in prisons in your country?	Yes
		No
10.2	Are opioid substitution therapy (OST) programmes operational in your country?	Yes
		No
10.2.1	Are opioid substitution therapy (OST) programmes operational in prisons in your country?	Yes
		No
10.3	Are drug dependence treatment interventions other than opioid substitution therapy implemented in the country?	Yes
		No
10.3.1	If yes, are they for:	Opioid dependence
		Non-opioid dependence
		Both
10.4	Is naloxone (used to reverse opioid overdoses) available through community distribution in your country?	Yes
		No
10.5	Do safe injection spaces/rooms exist?	Yes
		No
10.5.1	If yes please specify, number of spaces/rooms:	
10.6	Any further comments?	
	<b>Safe injecting practices among people who inject drugs</b>	
	This indicator is aligned with GAM 1.8. Guidance on responding to this question is available here.	<a href="https://www.unaids.org/sites/default/files/media_asset/global-aids-monitoring_en.pdf#page=29">https://www.unaids.org/sites/default/files/media_asset/global-aids-monitoring_en.pdf#page=29</a>
10.7	Are data available?	Yes
		No
10.7.1	Data measurement tool / source	Behavioural Surveillance Survey
		Special Study
		Other

10.7.1.1	Other measurement tool / source	
10.7.2	Please specify sampling strategy and location:	
10.7.3	Data Collection Period From:	
10.7.4	Data Collection Period To:	
10.7.5	Additional information related to entered data. e.g. reference to primary data source, methodological concerns:	
10.7.6	If available, upload a relevant supporting document by clicking on the icon. Any standard file format is acceptable, but it must be less than 8MB in size. When it has uploaded successfully, a unique ID will appear in the box.	
10.7.7	Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source:	
10.7.8	Sample size - Number of Survey Respondents	
10.7.9		
10.7.9	<b>Numerator: Number of people who inject drugs who report using sterile injecting equipment in the last month</b>	
	All	
10.7.9.1	<b>Denominator: Number of people who inject drugs who responded to the survey</b>	
	All	
10.7.9.2	<b>Percentage (%): Percentage of people who inject drugs reporting the use of sterile injecting equipment in the last month</b>	
	All	#DIV/0!
	<b>I. Percentage of people who inject drugs reporting using sterile injecting equipment the last time they injected</b>	
10.7.10	Are data available?	Yes
		No
10.7.11	Data measurement tool / source	Behavioural Surveillance Survey
		Special Study
		Other
10.7.11.1	Other measurement tool / source	
10.7.12	Please specify sampling strategy and location:	
10.7.13	Data Collection Period From:	
10.7.14	Data Collection Period To:	
10.7.15	Additional information related to entered data. e.g. reference to primary data source, methodological concerns:	
10.7.16	If available, upload a relevant supporting document by clicking on the icon. Any standard file format is acceptable, but it must be less than 8MB in size. When it has uploaded successfully, a unique ID will appear in the box.	
10.7.17	Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source:	
10.7.18	Sample size - Number of Survey Respondents	
10.7.19		
	<b>Numerator: Number of people who inject drugs who report using sterile injecting equipment the last time they injected drugs</b>	

<b>10.7.19</b>	All	
<b>10.7.19.3</b>	Males	
<b>10.7.19.6</b>	Females	
<b>10.7.19.9</b>	Transgender	
<b>10.7.19.12</b>	<25	
<b>10.7.19.15</b>	25+	
	<b>Denominator: Number of people who inject drugs who report injecting drugs in the past month</b>	
<b>10.7.19.1</b>	All	
<b>10.7.19.4</b>	Males	
<b>10.7.19.7</b>	Females	
<b>10.7.19.10</b>	Transgender	
<b>10.7.19.13</b>	<25	
<b>10.7.19.16</b>	25+	
	<b>Percentage (%): Percentage of people who inject drugs reporting the use of sterile injecting equipment the last time they injected</b>	
<b>10.7.19.2</b>	All	#DIV/0!
<b>10.7.19.5</b>	Males	#DIV/0!
<b>10.7.19.8</b>	Females	#DIV/0!
<b>10.7.19.11</b>	Transgender	#DIV/0!
<b>10.7.19.14</b>	<25	#DIV/0!
<b>10.7.19.17</b>	25+	#DIV/0!

Needles and syringes distributed per person who injects drugs

This form is pre-populated with data reported in the previous data collection round. Previously entered data is shown below each data entry field. Please enter new data if available. If no new data are available, please review and enter the data from the previous dataset in the data entry field.

DDM 2024	Question	Response
	This indicator is aligned with GAM 1.9. Guidance on responding to this question is available here.	<a href="https://www.unaids.org/sites/default/files/media_asset/global-aids-monitoring_en.pdf#page=31">https://www.unaids.org/sites/default/files/media_asset/global-aids-monitoring_en.pdf#page=31</a>
10.8	Are data available?	Yes
		No
10.8.1	Data measurement tool / source	National programme data
		Other (please specify)
10.8.1.1	Other measurement tool / source	
10.8.2	Please specify sampling strategy and location:	
10.8.3	Data Collection Period From:	
10.8.4	Data Collection Period To:	
10.8.5	Additional information related to entered data:	
10.8.6	If available, upload a relevant supporting document by clicking on the icon. Any file format is acceptable, but it must be less than 8MB in size. When it has uploaded successfully, a unique ID will appear in the box.	
10.8.7	Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source:	
	Please provide disaggregations by provider if available. For a definition of key-population led organisations, see UNAIDS guidance here. 'Other entities' could include private for-profit and non-profit organisations which are not key-population led, including national and international nongovernmental organisations.	<a href="https://www.unaids.org/sites/default/files/media_asset/UNAIDS_GAM_Framework_2022_EN.pdf#page=33">https://www.unaids.org/sites/default/files/media_asset/UNAIDS_GAM_Framework_2022_EN.pdf#page=33</a>
	<b>Numerator: Number of needles and syringes distributed in the past 12 months by NSPs</b>	
10.8.8	Total	
10.8.8.3	Public Sector	
10.8.8.6	Key populations-led organization	
10.8.8.9	Other entities	
	<b>Denominator: Number of people who inject drugs in the country</b>	
10.8.8.1	Total	
10.8.8.4	Public Sector	
10.8.8.7	Key populations-led organization	
10.8.8.10	Other entities	
	<b>Percentage (%): Number of needles and syringes distributed per person who injects drugs per year by needle and syringe programmes</b>	
10.8.8.2	Total	#DIV/0!
10.8.8.5	Public Sector	#DIV/0!
10.8.8.8	Key populations-led organization	#DIV/0!
10.8.8.11	Other entities	#DIV/0!

Coverage of opioid substitution therapy

This form is pre-populated with data reported in the previous data collection round. Previously entered data is shown below each data entry field. Please enter new data if available. If no new data are available, please review and enter the data from the previous dataset in the data entry field.

DDM 202	Question	Response
	<div>This indicator is aligned with GAM 1.10. Guidance on responding to this question is available <a href="https://www.unaids.org/sites/default/files/media_asset/global-aids-monitoring_en.pdf#page=33">here</a>.</div>	<a href="https://www.unaids.org/sites/default/files/media_asset/global-aids-monitoring_en.pdf#page=33">https://www.unaids.org/sites/default/files/media_asset/global-aids-monitoring_en.pdf#page=33</a>
10.9	Are data available?	Yes
		No
10.9.1	Data measurement tool / source	National programme data
		Other (please specify)
10.9.1.1	Other measurement tool / source	
10.9.2	Please specify sampling strategy and location:	
10.9.3	Data Collection Period From:	
10.9.4	Data Collection Period To:	
10.9.5	Additional information related to entered data:	
10.9.6	If available, upload a relevant supporting document by clicking on the icon. Any file format is acceptable, but it must be less than 8MB in size. When it has uploaded successfully, a unique ID will appear in the box.	
10.9.7	Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source:	
10.9.8	Provide disaggregations by sex, transgender and age if available.	
	Numerator: Number of people who inject drugs and are receiving opioid substitution therapy at a specified date (inc. disaggregations by age, gender and type of provider)	
10.9.8	Total	
10.9.8.3	Males	
10.9.8.6	Females	
10.9.8.9	Transgender	
10.9.8.12	<25	
10.9.8.15	25+	
	Denominator: Number of opioid-dependent people who inject drugs in the country (inc. disaggregations by age, gender and type of provider)	
10.9.8.1	Total	
10.9.8.4	Males	
10.9.8.7	Females	
10.9.8.10	Transgender	
10.9.8.13	<25	
10.9.8.16	25+	
	Percentage (%): Percentage of people who inject drugs receiving opioid substitution therapy at a specified date	
10.9.8.2	Total	#DIV/0!
10.9.8.5	Males	#DIV/0!
10.9.8.8	Females	#DIV/0!
10.9.8.11	Transgender	#DIV/0!
10.9.8.14	<25	#DIV/0!
10.9.8.17	25+	#DIV/0!

10.9.9	Please provide disaggregations by provider if available. For a definition of key-population led organisations, see UNAIDS guidance here. 'Other entities' could include private for-profit and non-profit organisations which are not key-population led, including national and international nongovernmental organisations.	<a href="https://www.unaids.org/sites/default/files/media_asset/UNAIDS_GAM_Framework_2022_EN.pdf#page=33">https://www.unaids.org/sites/default/files/media_asset/UNAIDS_GAM_Framework_2022_EN.pdf#page=33</a>
	Numerator: Number of people who inject drugs and are receiving opioid substitution therapy at a specified date (inc. disaggregations by age, gender and type of provider)	
10.9.9	Public Sector	
10.9.9.3	Key populations-led organization	
10.9.9.6	Other entities	
	Denominator: Number of opioid-dependent people who inject drugs in the country (inc. disaggregations by age, gender and type of provider)	
10.9.9.1	Public Sector	
10.9.9.4	Key populations-led organization	
10.9.9.7	Other entities	
	Percentage (%): Percentage of people who inject drugs receiving opioid substitution therapy at a specified date	
10.9.9.2	Public Sector	#DIV/0!
10.9.9.5	Key populations-led organization	#DIV/0!
10.9.9.8	Other entities	#DIV/0!



**PREP POLICY AND PROVISION**

This form is pre-populated with data reported in the previous data collection round. Previously entered data is shown below each data entry field. Please enter new data if available. If no new data are available, please review and enter the data from the previous dataset in the data entry field.

DDM 2024	Question	Response
11.1.1	Has the WHO and/or EACS recommendations on oral PrEP been adopted in your country's national guidelines?	Yes, PrEP guidelines have been developed and are being implemented
		Yes, PrEP guidelines have been developed but are not yet being implemented
		No, guidelines have not been developed
11.1.1.1	If yes, please provide a link to your PrEP guidelines. If they are not online, please upload below.	
11.1.1.2	Upload PrEP guidelines here by clicking on the icon. Any file format is acceptable, but it must be less than 8MB in size. When it has uploaded successfully, a unique ID will appear in the box.	
11.1.2	If the WHO and/or EACS recommendation on oral PrEP has not yet been adopted in the national guidelines, is there a plan to adopt a PrEP recommendation in the future?	Yes
		No
11.1.3	If yes, please indicate the year when adoption of the PrEP recommendations into national guidelines is planned:	
		2024
		2025
		2026
		2027
11.1.3.1		Other (please specify): _____
		No planned year
11.1.3.2	Are PrEP guidelines or recommendations being implemented as a national government funded programme?	Yes
		No
11.1.3.3	If yes, are cost of the drug fully or partially reimbursed?	Fully reimbursed
		Partially reimbursed
11.1.3.4	If no, is PrEP available in any of the following ways?	Nationally available for purchase, either as branded or generic drugs – but all cost covered by the individual (not reimbursed)
		Nationally available for purchase, either as branded or generic drugs – but cost partially covered by the individual (partially reimbursed)
		Available through pilot or research projects
		Not formally available at all
11.1.4	Which of the following constraints, if any, are limiting or preventing PrEP scale-up in your country? (please select all that apply):	Long waiting lists (capacity constraints despite a national programme being in place)
		PrEP not available in all parts/regions of the country
		Difficulty reaching certain key population groups
		Stigma and discrimination
		Cost of the drug
		Cost of service delivery
		The technical capacity to consider PrEP is limited
11.1.4.1		Other (please specify): _____
11.1.4.2	If you experience difficulties reaching certain key population groups, please specify which:	Gay men and other men who have sex with men
		Sex workers
		People who inject drugs
		Transgender people
		Prisoners
		Migrants (documented)
		Migrants (undocumented)
11.1.4.3		Other (please specify): _____
11.1.5	If national PrEP guidelines have been developed, please specify for which populations PrEP is, or will be, provided as per the guidelines:	To be determined
		Gay men and other men who have sex with men
		Sex workers
		People who inject drugs
		Transgender people
		Serodiscordant couples

		Heterosexuals at risk of sexual acquisition of HIV
		Prisoners
11.1.5.1		Other (please specify): _____
11.1.6	If national PrEP guidelines have been developed, is PrEP available to undocumented migrants if they meet the eligibility criteria (e.g. if they are a gay man or heterosexual at risk of sexual acquisition of HIV)?	Yes
		No
11.1.6.1		Other (please specify): _____
11.1.7	If national PrEP guidelines have been developed, who has the authority to prescribe PrEP in your country (please select all that apply)?	Doctors
		Clinical officers
		Nursing cadre (e.g., midwives, nurse practitioners and registered nurses)
		Pharmacists
11.1.7.1		Other (please specify): _____
11.1.8	Is PrEP available through any of the following in your country (please select all that apply):	
		Sexual health clinics (public)
		Infectious disease clinics (public)
		Primary care (public)
		Specialised HIV clinics (public)
		Private providers
		NGO/community settings
11.1.18.1		Other (please specify): _____
11.1.9	Is there any law or regulation prohibiting individuals from purchasing PrEP online from abroad?	Yes
		No
	<b>In these settings, what is the cost to the individual when receiving PrEP?</b>	
11.1.10	<b>What is the cost to the individual when receiving PrEP through research (including pilot studies and demonstration projects)?</b>	
	Cost of drugs (if available at a cost, please specify whether branded or generic drugs are available)	Available free for all individuals
		Free if the individual has insurance
		Generic drugs available at a cost
		Branded drugs available at a cost
q11_1_10_spec		Other (please specify)
q11_1_10_1	Cost of renal function and bone density monitoring	Available free for all individuals
		Free if the individual has insurance
		Available at a cost
q11_1_10_1_spec		Other (please specify)
q11_1_10_2	Cost of STI screening	Available free for all individuals
		Free if the individual has insurance
		Available at a cost
q11_1_10_2_spec		Other (please specify)
11.1.10.3	Any other cost?	
11.1.10.4	Additional comments:	
11.1.11	<b>What is the cost to the individual when receiving PrEP through public facilities - sexual health clinics, infectious disease clinics and primary care?</b>	
11.1.11	Cost of drugs	Available free for all individuals
		Free if the individual has insurance
		Generic drugs available at a cost
		Branded drugs available at a cost
q11_1_11_spec		Other (please specify)
11.1.11.1	Cost of renal function and bone density monitoring	Available free for all individuals
		Free if the individual has insurance
		Available at a cost
q11_1_11_1_spec		Other (please specify)
11.1.11.2	Cost of STI screening	Available free for all individuals
		Free if the individual has insurance
		Available at a cost

q11_1_11_2_spec		Other (please specify)
11.1.11.3	Any other cost?	
11.1.11.4	Additional comments:	
11.1.12	<b>What is the cost to the individual when receiving PrEP through private providers?</b>	
	Cost of drugs	Available free for all individuals
		Free if the individual has insurance
		Generic drugs available at a cost
		Branded drugs available at a cost
q11_1_12_spec		Other (please specify)
11.1.12.1	Cost of renal function and bone density monitoring	Available free for all individuals
		Free if the individual has insurance
		Available at a cost
q11_1_12_1_spec		Other (please specify)
11.1.12.2	Cost of STI screening	Available free for all individuals
		Free if the individual has insurance
		Available at a cost
q11_1_12_2_spec		Other (please specify)
11.1.12.3	Any other cost?	
11.1.13	Any further comments?	
11.1.14	Has long-acting injectable cabotegravir for PrEP been authorised for use in your country?	Yes
		No
11.1.15	If yes, what is the status of introducing, or using, long-acting cabotegravir for PrEP?	Recommended in national guidelines and implemented
		Recommended in national guidelines but not implemented
		Guidelines including long-acting injectables under development/being considered
		Long-acting injectable PrEP is currently not being considered
11.1.15.1		Other (if yes please specify)
11.1.16	If no, are there plans to do so in the coming two years?	Yes in 2024
		Yes in 2025
11.1.16.1		Other year
		No

## People who received pre-exposure prophylaxis

This form is pre-populated with data reported in the previous data collection round. Previously entered data is shown below each data entry field. Please enter new data if available. If no new data are available, please review and enter the data from the previous dataset in the data entry field.

DDM 2024	Question	Response
	This indicator is aligned with GAM 1.11. Guidance on responding to this question is available <a href="http://www.unaids.org/sites/default/files/media_asset/global-aids-monitoring_en.pdf#page=34">here</a> .	<a href="http://www.unaids.org/sites/default/files/media_asset/global-aids-monitoring_en.pdf#page=34">http://www.unaids.org/sites/default/files/media_asset/global-aids-monitoring_en.pdf#page=34</a>
11.2.1	Are data available?	Yes
		No
11.2.2	Data measurement tool / source	Antiretroviral Therapy Patient Registers
		Other tools (please define data sources below)
	If data are available on people receiving PrEP from surveys, such as Integrated Bio-Behavioural Surveys, please provide information on the type of survey, the numerator and denominator in the comment box on "Data related to the topic which does not fit into the indicator cells." Please upload a copy of the survey report below.	
11.2.2.1	Other measurement tool / source	
11.2.3	Data Collection Period From:	
11.2.4	Data Collection Period To:	
11.2.5	Additional information related to entered data. e.g. reference to primary data source, methodological concerns:	
11.2.6	If available, upload a relevant supporting document by clicking on the icon. Any file format is acceptable, but it must be less than 8MB in size. When it has uploaded successfully, a unique ID will appear in the box.	
11.2.7	Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source:	
	<b>Disaggregated by sex</b>	
11.2.8	Please provide disaggregations by sex if available	
	<b>Number of people (aged 15+) who received PrEP at least once during the reporting period</b>	

11.2.8	Total	
11.2.8.2	Males	
11.2.8.4	Females	
11.2.8.6	Transgender	
11.2.8.8	Sex unknown	
	<b>Number of people (aged 15+) who received PrEP for the first time in their lives during the reporting period</b>	
11.2.8.1	Total	
11.2.8.3	Males	
11.2.8.5	Females	
11.2.8.7	Transgender	
11.2.8.9	Sex unknown	
	<b>Disaggregated by key population</b>	
11.2.9	<b>Please provide disaggregations by key population if available.</b>	
	<b>Number of people (aged 15+) who received PrEP at least once during the reporting period</b>	
11.2.9	Men who have sex with men	
11.2.9.2	People who inject drugs	
11.2.9.4	Migrants (persons born abroad)	
11.2.9.6	Sex workers	
11.2.9.8	Prisoners	
	<b>Number of people (aged 15+) who received PrEP for the first time in their lives during the reporting period</b>	
11.2.9.1	Men who have sex with men	
11.2.9.3	People who inject drugs	
11.2.9.5	Migrants (persons born abroad)	
11.2.9.7	Sex workers	
11.2.9.9	Prisoners	
11.2.9.10	<b>Do you have data on the number of individuals within the following populations who are in need of PrEP according to your prescribing guidelines?</b>	
	Men who have sex with men	Yes
	Migrants (persons born abroad)	No

	People who inject drugs	
	Sex workers	
	Prisoners	
	Transgender People	
	Women	
	<b>What percentage of this need is being met?</b>	
11.2.9.11	Men who have sex with men	
11.2.9.12	Migrants (persons born abroad)	
11.2.9.13	People who inject drugs	
11.2.9.14	Sex workers	
11.2.9.15	Prisoners	
11.2.9.16	Transgender People	
11.2.9.17	Women	
11.2.10	<b>If you would like to submit regional or city-specific data please upload a file with additional data by clicking on the icon:</b>	







**PrEP: UNIT PRICES**

This form is pre-populated with data reported in the previous data collection round. Previously entered data is shown below each data entry field. Please enter new data if available. If no new data are available, please review and enter the data from the previous dataset in the data entry field.

DDM 2024	Question	Response
	Please note: ECDC will anonymise country pricing in any analysis and this will be checked with countries before publication.	
Q11.3.1	Are you able to provide information on the current cost (procurement cost) of a month's supply of government-purchased PrEP (28-30 tablets) in your country?	PrEP not purchased by government
		Yes
		No
Q11.3.1.1	Which type of PrEP is government-purchased in your country?	Truvada (branded)
		Tenofovir disoproxil (TDF) / Emtricitabine (FTC) (generics)
		Tenofovir disoproxil (TDF) / Lamivudine (3TC) (generics)
		Tenofovir disoproxil (TDF) (generics)
	<b>Truvada (branded)</b>	
Q11.3.1.2	Cost (in euros) of 28-30 tablets <i>If available from multiple manufacturers, please provide the cost of the cheapest option.</i>	
	<b>Tenofovir disoproxil (TDF) / Emtricitabine (FTC) (generics)</b>	
Q11.3.1.3	Cost (in euros) of 28-30 tablets <i>If available from multiple manufacturers, please provide the cost of the cheapest option.</i>	
	<b>Tenofovir disoproxil (TDF) / Lamivudine (3TC) (generics)</b>	
Q11.3.1.4	Cost (in euros) of 28-30 tablets <i>If available from multiple manufacturers, please provide the cost of the cheapest option.</i>	
	<b>Tenofovir disoproxil (TDF) (generics)</b>	

Q11.3.1.5	Cost (in euros) of 28-30 tablets <i>If available from multiple manufacturers, please provide the cost of the cheapest option.</i>	
Q11.3.2	<b>Are you able to provide information on the current cost (cost to the user) of a month's supply of PrEP (28-30 tablets) purchased through a pharmacy or clinic with a prescription in your country?</b>	PrEP not available in pharmacies or clinics
		Yes
		No
Q11.3.2.1	Which type of PrEP is available through pharmacies or clinics with a prescription in your country?	Truvada (branded)
		Tenofovir disoproxil (TDF) / Emtricitabine (FTC) (generics)
		Tenofovir disoproxil (TDF) / Lamivudine (3TC) (generics)
		Tenofovir disoproxil (TDF) (generics)
	<b>Truvada (branded)</b>	
Q11.3.2.2	Cost (EUR) of 28-30 tablets before any reimbursement	
Q11.3.2.3	Cost (EUR) of 28-30 tablets after any reimbursement	
	<b>Tenofovir disoproxil (TDF) / Emtricitabine (FTC) (generics)</b>	
Q11.3.2.4	Cost (EUR) of 28-30 tablets before any reimbursement	
Q11.3.2.5	Cost (EUR) of 28-30 tablets after any reimbursement	
	<b>Tenofovir disoproxil (TDF) / Lamivudine (3TC) (generics)</b>	
Q11.3.2.6	Cost (EUR) of 28-30 tablets before any reimbursement	
Q11.3.2.7	Cost (EUR) of 28-30 tablets after any reimbursement	
	<b>Tenofovir disoproxil (TDF) (generics)</b>	
Q11.3.2.8	Cost (EUR) of 28-30 tablets before any reimbursement	
Q11.3.2.9	Cost (EUR) of 28-30 tablets after any reimbursement	
11.4	Any further comments?	





## HIV TESTING POLICY AND PROVISION

This form is pre-populated with data reported in the previous data collection round. Previously entered data is shown below each data entry field. Please enter new data if available. If no new data are available, please review and enter the data from the previous dataset in the data entry field.

DDM 2024	Question	Response	
13.1	Is there a national policy/strategy or other recommendations from your government on HIV testing?	Yes	
		No	
13.1.1	If yes, please provide a link to your testing guidelines. If they are not online, please upload them below.		
13.1.2	Upload testing guidelines by clicking on the icon. Any file format is acceptable, but it must be less than 8MB in size. When it has uploaded successfully, a unique ID will appear in the box.		
13.1.3	What year were the guidelines published?	Yes	
		No	
13.1.4	Are there plans to revise these guidelines?	Yes	
		No	
13.1.4.1	If yes, what year will they be revised?	No planned year	
		2024	
		2025	
		2026	
		2027	
		2028	
13.1.5	Do the guidelines have content on specific key populations?	Yes	
		No	
13.1.5.1	If yes, which key populations? Please select all that apply:	Men who have sex with men	
		People who inject drugs	

		Migrants	
		Sex workers	
		Former and/or current prisoners	
		Transgender people	
		Other (please specify)	
13.1.5.2	Please specify:		
13.1.6	Do the guidelines make recommendations on how often certain groups should be tested for HIV?	Yes	
		No	
13.1.6.1	<b>If yes, how often are the following key populations recommended to test for HIV?</b>		
13.1.6.1	General population	Not mentioned in guidance	
		At least once in a lifetime	
		At least once a year	
		Every 6 months	
		Every 3 months	
13.1.6.1.0		Other (please specify)	
13.1.6.2	MSM	Not mentioned in guidance	
		At least once in a lifetime	
		At least once a year	
		Every 6 months	
		Every 3 months	
13.1.6.2.0		Other (please specify)	
13.1.6.3	PWID	Not mentioned in guidance	
		At least once in a lifetime	
		At least once a year	
		Every 6 months	
		Every 3 months	
13.1.6.3.0		Other (please specify)	

## ECDC NORMAL

<b>13.1.6.4</b>	Migrants	Not mentioned in guidance	
		At least once in a lifetime	
		At least once a year	
		Every 6 months	
		Every 3 months	
<b>13.1.6.4.0</b>		Other (please specify)	
<b>13.1.6.5</b>	Sex workers	Not mentioned in guidance	
		At least once in a lifetime	
		At least once a year	
		Every 6 months	
		Every 3 months	
<b>13.1.6.5.0</b>		Other (please specify)	
<b>13.1.6.6</b>	Formers and/or current prisoners	Not mentioned in guidance	
		At least once in a lifetime	
		At least once a year	
		Every 6 months	
		Every 3 months	
<b>13.1.6.6.0</b>		Other (please specify)	
<b>13.1.6.7</b>	Trans people	Not mentioned in guidance	
		At least once in a lifetime	
		At least once a year	
		Every 6 months	
		Every 3 months	
<b>13.1.6.7.0</b>		Other (please specify)	
<b>13.1.6.8</b>	Additional comments:		
<b>13.1.7</b>	If no, are any of the following guidance documents used as a substitute for national testing strategy or guidance?		

## ECDC NORMAL

		ECDC Public health guidance on HIV, hepatitis B and C testing in the EU/EEA (2018)	
		WHO Consolidated guidelines on HIV testing services (2019)	
<b>13.1.7.1</b>		Other guidelines (please specify)	
		None of the above	
13.1.8	If no, are there plans to introduce a national policy/strategy or other recommendations from your government on HIV testing in the next two years?	Yes	
		No	
13.2	Do national testing guidelines include recommendations for <u>integrated testing</u> for HIV, viral hepatitis and sexually transmitted infections, in line with ECDC Public health guidance on HIV, hepatitis B and C testing in the EU/EEA (2018)?	Yes, there are guidelines for <u>integrated</u> HIV, viral hepatitis and sexually transmitted infections testing	<a href="https://www.ecdc.europa.eu/en/publications-data/public-health-guidance-hiv-hepatitis-b-and-c-testing-eueea">https://www.ecdc.europa.eu/en/publications-data/public-health-guidance-hiv-hepatitis-b-and-c-testing-eueea</a>
		Yes, there are guidelines for <u>integrated</u> HIV and viral hepatitis testing	
		No, guidelines do not include recommendations on <u>integrated testing</u>	
<b>13.2.1</b>		Other, please specify	
13.2.2	If no or other, are there plans to revise national testing guidelines to introduce recommendations for <u>integrated testing</u> for HIV, viral hepatitis and sexually transmitted infections?	Yes	
		No	
		Don't know	
13.2.3	If yes, What year will they be revised?	No planned year	



		2024	
		2025	
		2026	
		2027	
		2028	
13.4	Which of the following HIV testing approaches are included in national testing guidelines? (please select all that apply):		
		Routine HIV testing and counselling in sexual health clinics	
		Routine antenatal HIV testing	
		Community-based HIV testing and counselling (by a medically trained professional)	
		Community-based HIV testing and counselling (by a lay provider)	
		Provider-initiated HIV testing in primary care	
		Provider-initiated HIV testing in secondary care	
		HIV testing in other health settings (e.g. pharmacies)	
		Home testing	
		Self-testing	
		Assisted partner notification/index testing	
		HIV indicator condition testing	
		None of the above	
13.5	Which of the following HIV testing approaches are used in your country (please select all that apply):		
		Routine HIV testing and counselling in sexual health clinics	
		Routine antenatal HIV testing	

		Community-based HIV testing and counselling (by a medically trained professional)	
		Community-based HIV testing and counselling (by a lay provider)	
		Provider-initiated HIV testing in primary care	
		Provider-initiated HIV testing in secondary care	
		HIV testing in other health settings (e.g. pharmacies)	
		Home testing	
		Self-testing	
		Assisted partner notification/index testing	
		HIV indicator condition testing	
		None of the above	
13.6	Are there any restrictions regarding who can legally carry out a HIV test?	Yes	
		No	
		Do not know	
13.6.1	If yes, who is able to carry out an HIV test? (Please select all that apply)	Specialist clinic doctor	
		Any doctor	
		Specialist clinic nurse	
		Any nurse	
		Community/NGO worker (with clinical supervision)	
		Community/NGO worker (without clinical supervision)	
13.6.1.1		Other (please specify)	
13.7	Is there restricted access to HIV testing for any of the following groups?		

		Men who have sex with men	
		People who inject drugs	
		Sex workers	
		Migrants	
		Undocumented migrants	
		Transgender people	
		Prisoners and incarcerated people	
		Other (please specify)	
		None of the above	
13.7.1	Please specify:		
13.8	Is HIV testing free for anyone who wishes to get tested?	Yes for all	
		Yes for certain people	
		No everyone has to pay	
13.9	Is HIV testing available...?	Across the whole country	
		Only in certain geographic areas	
		Not available	
13.10	How is HIV testing available to prisoners in your country?	Routinely offered to all prisoners (opt-out)	
		Available (opt in)	
		Not available	
		No national data	
		Other	
13.10.1	Please specify:		
13.11	Is HIV testing mandatory in prisons?	Mandatory for every prisoner	
		Mandatory for certain subgroups	
		Not mandatory	
		No national data	
13.12	Any further comments?		





## HIV TESTING VOLUME AND POSITIVITY

This form is pre-populated with data reported in the previous data collection round. Previously entered data is shown below each data entry field. Please enter new data if available. If no new data are available, please review and enter the data from the previous dataset in the data entry field.

DDM 2024	Question	Response
	<b>The number of HIV tests conducted (testing volume) and the percentage of HIV-positive results returned to people (positivity) in the calendar year</b>	
	<b>This indicator is aligned with GAM 2.5. Guidance on responding to this question is available here.</b>	<a href="http://www.unaids.org/sites/default/files/media_asset/global-aids-monitoring_en.pdf#page=52">http://www.unaids.org/sites/default/files/media_asset/global-aids-monitoring_en.pdf#page=52</a>
Q14.1	Are data available?	Yes
		No
Q14.1.1	Please specify any national testing campaigns or shifts in testing strategies that might explain any changes to testing volumes when compared to previous years	
Q14.1.2	Data on retesting rates among HIV-positive or HIV-negative individuals:	
Q14.1.3	Data measurement tool / source	HTS programme registers, log books and reporting forms
		Other
Q14.1.3.1	Other measurement tool / source	
Q14.1.4	Data Collection Period From:	
Q14.1.5	Data Collection Period To:	
<b>Q14.1.6</b>	<b>Additional information related to entered data. e.g. reference to primary data source, methodological concerns:</b>	
Q14.1.6.1	If available, upload a relevant supporting document by clicking on the icon. Any file format is acceptable, but it must be less than 8MB in size. When it has uploaded successfully, a unique ID will appear in the box.	
Q14.1.7	Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source:	
<b>Q14.1.8</b>		
	<b>Numerator: Number of tests conducted where an HIV-positive result was returned to a person (positivity)</b>	
Q14.1.8	Total	
Q14.1.8.3	Males 15+	
Q14.1.8.6	Females 15+	
	<b>Denominator: Number of tests performed where results were received by a person (testing volume)</b>	
Q14.1.8.1	Total	
Q14.1.8.4	Males 15+	
Q14.1.8.7	Females 15+	
	<b>Percentage (%): Percentage of HIV-positive results returned to people in the calendar year</b>	
Q14.1.8.2	Total	#DIV/0!
Q14.1.8.5	Males 15+	#DIV/0!
Q14.1.8.8	Females 15+	#DIV/0!
	<b>By testing modality: Facility-level testing</b>	
Q14.2	Are data available?	Yes
		No
<b>Q14.2.1</b>		
	<b>Numerator: Number of tests conducted where an HIV-positive result was returned to a person (positivity)</b>	
Q14.2.1	All facility-level testing	
Q14.2.1.3	Provider-initiated testing in clinics or emergency facilities	
Q14.2.1.6	Antenatal care clinics (including labour and delivery)	

Q14.2.1.9	VCT (within a health-facility setting)	
Q14.2.1.12	Family planning clinic	
Q14.2.1.15	Other facility-level testing	
	<b>Denominator: Number of tests performed where results were received by a person (testing volume)</b>	
Q14.2.1.1	All facility-level testing	
Q14.2.1.4	Provider-initiated testing in clinics or emergency facilities	
Q14.2.1.7	Antenatal care clinics (including labour and delivery)	
Q14.2.1.10	VCT (within a health-facility setting)	
Q14.2.1.13	Family planning clinic	
Q14.2.1.16	Other facility-level testing	
	<b>Percentage (%): Percentage of HIV-positive results returned to people in the calendar year</b>	
Q14.2.1.2	All facility-level testing	#DIV/0!
Q14.2.1.5	Provider-initiated testing in clinics or emergency facilities	#DIV/0!
Q14.2.1.8	Antenatal care clinics (including labour and delivery)	#DIV/0!
Q14.2.1.11	VCT (within a health-facility setting)	#DIV/0!
Q14.2.1.14	Family planning clinic	#DIV/0!
Q14.2.1.17	Other facility-level testing	#DIV/0!
Q14.2.2	If available, upload a relevant supporting document by clicking on the icon. Any file format is acceptable, but it must be less than 8MB in size. When it has uploaded successfully, a unique ID will appear in the box.	
	<b>By testing modality: Community-level HTS reporting</b>	
Q14.3	Are data available?	
		Reactive tests in community-level HTS
		Positive tests in community-level HTS
		Clients receiving reactive tests in community-level HTS
		Clients receiving positive tests in community-level HTS
		No data available
Q14.3.1	<b>Reactive tests</b>	
	<b>Numerator: Number of tests conducted where an HIV-reactive result was returned to a person (reactivity)</b>	
Q14.3.1	All community-level HTS reporting	
Q14.3.1.3	VCT centres (not within a health facility setting)	
Q14.3.1.6	Mobile testing	
Q14.3.1.9	Other community-based testing	
	<b>Denominator: Number of tests performed where results were received by a person (testing volume)</b>	
Q14.3.1.1	All community-level HTS reporting	
Q14.3.1.4	VCT centres (not within a health facility setting)	
Q14.3.1.7	Mobile testing	
Q14.3.1.10	Other community-based testing	
	<b>Percentage (%): Percentage of HIV-reactive results returned to people in the calendar year (reactivity)</b>	
Q14.3.1.2	All community-level HTS reporting	#DIV/0!
Q14.3.1.5	VCT centres (not within a health facility setting)	#DIV/0!
Q14.3.1.8	Mobile testing	#DIV/0!
Q14.3.1.11	Other community-based testing	#DIV/0!
Q14.3.1.12	If available, upload a relevant supporting document by clicking on the icon. Any file format is acceptable, but it must be less than 8MB in size. When it has uploaded successfully, a unique ID will appear in the box.	
Q14.3.2	<b>Positive tests</b>	
	<b>Numerator: Number of tests conducted where an HIV-positive result was returned to a person (positivity)</b>	
Q14.3.2	All community-level HTS reporting	
Q14.3.2.3	VCT centres (not within a health facility setting)	

Q14.3.2.6	Mobile testing	
Q14.3.2.9	Other community-based testing	
	<b>Denominator: Number of tests performed where results were received by a person (testing volume)</b>	
Q14.3.2.1	All community-level HTS reporting	
Q14.3.2.4	VCT centres (not within a health facility setting)	
Q14.3.2.7	Mobile testing	
Q14.3.2.10	Other community-based testing	
	<b>Percentage (%): Percentage of HIV-reactive results returned to people in the calendar year (positivity)</b>	
Q14.3.2.2	All community-level HTS reporting	#DIV/0!
Q14.3.2.5	VCT centres (not within a health facility setting)	#DIV/0!
Q14.3.2.8	Mobile testing	#DIV/0!
Q14.3.2.11	Other community-based testing	#DIV/0!
Q14.3.2.12	If available, upload a relevant supporting document by clicking on the icon. Any file format is acceptable, but it must be less than 8MB in size. When it has uploaded successfully, a unique ID will appear in the box.	
Q14.3.3	<b>Clients receiving reactive results</b>	
	<b>Numerator: Number of clients receiving an HIV-reactive result (reactivity)</b>	
Q14.3.3	All community-level HTS reporting	
Q14.3.3.3	VCT centres (not within a health facility setting)	
Q14.3.3.6	Mobile testing	
Q14.3.3.9	Other community-based testing	
	<b>Denominator: Number of clients tested</b>	
Q14.3.3.1	All community-level HTS reporting	
Q14.3.3.4	VCT centres (not within a health facility setting)	
Q14.3.3.7	Mobile testing	
Q14.3.3.10	Other community-based testing	
	<b>Percentage (%): Percentage of clients receiving HIV-reactive results in the calendar year (reactivity)</b>	
Q14.3.3.2	All community-level HTS reporting	#DIV/0!
Q14.3.3.5	VCT centres (not within a health facility setting)	#DIV/0!
Q14.3.3.8	Mobile testing	#DIV/0!
Q14.3.3.11	Other community-based testing	#DIV/0!
Q14.3.3.12	If available, upload a relevant supporting document by clicking on the icon. Any file format is acceptable, but it must be less than 8MB in size. When it has uploaded successfully, a unique ID will appear in the box.	
Q14.3.4	<b>Clients receiving positive results</b>	
	<b>Numerator: Number of clients receiving an HIV-positive result (positivity)</b>	
Q14.3.4	All community-level HTS reporting	
Q14.3.4.3	VCT centres (not within a health facility setting)	
Q14.3.4.6	Mobile testing	
Q14.3.4.9	Other community-based testing	
	<b>Denominator: Number of clients tested</b>	
Q14.3.4.1	All community-level HTS reporting	
Q14.3.4.4	VCT centres (not within a health facility setting)	
Q14.3.4.7	Mobile testing	
Q14.3.4.10	Other community-based testing	
	<b>Percentage (%): Percentage of clients receiving HIV-positive results in the calendar year (positivity)</b>	
Q14.3.4.2	All community-level HTS reporting	#DIV/0!
Q14.3.4.5	VCT centres (not within a health facility setting)	#DIV/0!
Q14.3.4.8	Mobile testing	#DIV/0!
Q14.3.4.11	Other community-based testing	#DIV/0!



Q14.3.4.12	If available, upload a relevant supporting document by clicking on the icon. Any file format is acceptable, but it must be less than 8MB in size. When it has uploaded successfully, a unique ID will appear in the box.	
	<b>Proportion of all new HIV diagnoses in the calendar year with first reactive test conducted at a Community-Based Voluntary Counselling and Testing (CBVCT) service</b>	
Q14.3.5	Are data available?	Yes
		No
Q14.3.6	Numerator: Number of new HIV diagnoses in the calendar year with first reactive test conducted at CBVCT	
Q14.3.6.1	Denominator: Number of new HIV diagnoses in the calendar year	
Q14.3.6.2	Percentage (%): Percentage of new HIV diagnoses in the calendar year with first reactive test conducted at a Community-Based Voluntary Counselling and Testing (CBVCT) service	#DIV/0!
	<b>Home testing</b>	
14.4	Are data available?	Yes
Q14.4.1	Numerator: Number of samples taken at home where an HIV positive result was returned to a person	
Q14.4.1.1	Denominator: Number of samples taken at home where results were returned to a person (testing volume)	
Q14.4.1.2	Percentage (%): Percentage of HIV-positive results returned to people who have home tested in the calendar year	#DIV/0!
Q14.4.2	If available, upload a relevant supporting document by clicking on the icon. Any file format is acceptable, but it must be less than 8MB in size. When it has uploaded successfully, a unique ID will appear in the box.	
	<b>Self-testing</b>	
Q14.5.0	Are data available?	Yes
		No
Q14.5.1	Procured: Number of self-test kits purchased (not distributed or used) in a year by the national government, including (but not limited to) donors	
Q14.5.2	Number of individual self-test kits that were distributed in a year	
Q14.6	Any further comments?	

## HIV testing among men who have sex with men

This form is pre-populated with data reported in the previous data collection round. Previously entered data is shown below each data entry field. Please enter new data if available. If no new data are available, please review and enter the data from the previous dataset in the data entry field.

DDM 2024	Question	Response
15.1.0	Does your country collect data on HIV testing among MSM?	Yes
		No
15.1.0.1	If no, please scroll to the bottom of this form, select form status as 'Complete' and click on 'Save & Exit Form'.	
15.1	For which key populations do you have new data on testing rates?	
		Men who have sex with men
		People who inject drugs
		Migrants (persons born abroad)
		Sex workers
		Prisoners
		Transgender people
		No data available
	<b>HIV testing among men who have sex with men</b>	
	This indicator is aligned with GAM 1.4B. Guidance on responding to this question is available <a href="https://www.unaids.org/sites/default/files/media_asset/global-aids-monitoring_en.pdf#page=16">here</a> .	<a href="https://www.unaids.org/sites/default/files/media_asset/global-aids-monitoring_en.pdf#page=16">https://www.unaids.org/sites/default/files/media_asset/global-aids-monitoring_en.pdf#page=16</a>
15.1.1	Data measurement tool / source	Behavioural Surveillance Survey
		Special Study
		Other
15.1.1.1	Other measurement tool / source	
15.1.2	Please specify sampling strategy and location:	
15.1.3	Data Collection Period From:	
15.1.4	Data Collection Period To:	
15.1.5	Additional information related to entered data. e.g. reference to primary data source, methodological concerns:	
15.1.5.1	If available, upload a relevant supporting document by clicking on the icon. Any file format is acceptable, but it must be less than 10MB in size. When it has uploaded successfully, a unique ID will appear in the box.	
15.1.6	Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source:	
15.1.7	Sample size - number of survey respondents	
15.1.8	<b>Please provide disaggregations by age if available.</b>	
	<b>A: Number of men who have sex with men who have been tested and whose result is positive</b>	
15.1.8	All	
15.1.8.5	<25	
15.1.8.10	25+	
	<b>B: Number of men who have sex with men who have been tested in the last 12 months and whose result is negative</b>	
15.1.8.1	All	

15.1.8.6	<25	
15.1.8.11	25+	
	<b>Numerator (A+B): Number of men who have sex with men who know their HIV status</b>	
15.1.8.2	All	0
15.1.8.7	<25	0
15.1.8.12	25+	0
	<b>Denominator: Number of men who have sex with men who responded to the question "Do you know your HIV status from an HIV test?"</b>	
15.1.8.3	All	
15.1.8.8	<25	
15.1.8.13	25+	
	<b>Percentage (%): Percentage of men who have sex with men who know their HIV status</b>	
15.1.8.4	All	#DIV/0!
15.1.8.9	<25	#DIV/0!
15.1.8.14	25+	#DIV/0!

HIV testing among people who inject drugs

This form is pre-populated with data reported in the previous data collection round. Previously entered data is shown below each data entry field. Please enter new data if available. If no new data are available, please review and enter the data from the previous dataset in the data entry field.

DDM 2024	Question	Response
15.2.0	Does your country collect data on HIV testing among people who inject drugs?	Yes
		No
15.2.0.1	If no, please scroll to the bottom of this form, select form status as 'Complete' and click on 'Save & Exit Form'.	
	This indicator is aligned with GAM 1.4C. Guidance on responding to this question is available here.	<a href="https://www.unaids.org/sites/default/files/media_asset/global-aids-monitoring_en.pdf#page=16">https://www.unaids.org/sites/default/files/media_asset/global-aids-monitoring_en.pdf#page=16</a>
15.2.1	Data measurement tool / source	Behavioural Surveillance Survey
		Special Study
		Other
15.2.1.1	Other measurement tool / source	
15.2.2	Please specify sampling strategy and location:	
15.2.3	Data Collection Period From:	
15.2.4	Data Collection Period To:	
15.2.5	Additional information related to entered data. e.g. reference to primary data source, methodological concerns:	
15.2.5.1	If available, upload a relevant supporting document by clicking on the icon. Any file format is acceptable, but it must be less than 8MB in size. When it has uploaded successfully, a unique ID will appear in the box.	
15.2.6	Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source:	
15.2.7	Sample size - number of survey respondents	
15.2.8		
	A: Number of people who inject drugs who have been tested and whose result is positive	
15.2.8	All	
15.2.8.5	Males	
15.2.8.10	Females	
15.2.8.15	Transgender	
15.2.8.20	<25	
15.2.8.25	25+	
	B: Number of people who inject drugs who have been tested in the last 12 months and whose result is negative	
15.2.8.1	All	
15.2.8.6	Males	
15.2.8.11	Females	
15.2.8.16	Transgender	
15.2.8.21	<25	
15.2.8.26	25+	
	Numerator (A+B): Number of people who inject drugs who know their HIV status	
15.2.8.2	All	0
15.2.8.7	Males	0
15.2.8.12	Females	0
15.2.8.17	Transgender	0
15.2.8.22	<25	0
15.2.8.27	25+	0

	Denominator: Number of people who inject drugs who responded to the question "Do you know your HIV status from an HIV test?"	
15.2.8.3	All	
15.2.8.8	Males	
15.2.8.13	Females	
15.2.8.18	Transgender	
15.2.8.23	<25	
15.2.8.28	25+	
	Percentage (%): Percentage of people who inject drugs who know their HIV status	
15.2.8.4	All	#DIV/0!
15.2.8.9	Males	#DIV/0!
15.2.8.14	Females	#DIV/0!
15.2.8.19	Transgender	#DIV/0!
15.2.8.24	<25	#DIV/0!
15.2.8.29	25+	#DIV/0!

HIV testing among migrants (persons born abroad)

This form is pre-populated with data reported in the previous data collection round. Previously entered data is shown below each data entry field. Please enter new data if available. If no new data are available, please review and enter the data from the previous dataset in the data entry field.

DDM 2024	Question	Response
15.3.0	Does your country collect data on HIV testing among migrants (people born abroad)?	Yes
		No
15.3.0.1	If no, please scroll to the bottom of this form, select form status as 'Complete' and click on 'Save & Exit Form'.	
15.3.1	Data measurement tool / source	Behavioural Surveillance Survey
		Special Study
		Other
15.3.1.1	Other measurement tool / source	
15.3.2	Please specify sampling strategy and location:	
15.3.3	Data Collection Period From:	
15.3.4	Data Collection Period To:	
15.3.5	Additional information related to entered data. e.g. reference to primary data source, methodological concerns:	
15.3.5.1	If available, upload a relevant supporting document by clicking on the icon. Any file format is acceptable, but it must be less than 8MB in size. When it has uploaded successfully, a unique ID will appear in the box.	
15.3.6	Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source:	
15.3.7	Sample size - number of survey respondents	
15.3.8	Please provide disaggregations by sex, transgender status and age if available.	
	A. Number of migrants who have been tested and whose result is positive	
15.3.8	All	
15.3.8.5	Males	
15.3.8.10	Females	
15.3.8.15	Transgender	
15.3.8.20	<25	
15.3.8.25	25+	
	B: Number of migrants who have been tested in the last 12 months and whose result is negative	
15.3.8.1	All	
15.3.8.6	Males	
15.3.8.11	Females	
15.3.8.16	Transgender	
15.3.8.21	<25	
15.3.8.26	25+	
	Numerator (A+B): Number of migrants who know their HIV status	
15.3.8.2	All	0
15.3.8.7	Males	0
15.3.8.12	Females	0
15.3.8.17	Transgender	0
15.3.8.22	<25	0
15.3.8.27	25+	0
	Denominator: Number of migrants who responded to the question "Do you know your HIV status from an HIV test?"	
15.3.8.3	All	
15.3.8.8	Males	

15.3.8.13	Females	
15.3.8.18	Transgender	
15.3.8.23	<25	
15.3.8.28	25+	
	Percentage (%): Percentage of migrants who know their HIV status	
15.3.8.4	All	#DIV/0!
15.3.8.9	Males	#DIV/0!
15.3.8.14	Females	#DIV/0!
15.3.8.19	Transgender	#DIV/0!
15.3.8.24	<25	#DIV/0!
15.3.8.29	25+	#DIV/0!
	Disaggregation by migration status	
15.3.9	Are new data on testing rates among undocumented migrants available?	Yes
		No
15.3.10	Please provide disaggregations by sex, transgender status and age if available.	
	A: Number of undocumented migrants who have been tested and whose result is positive	
15.3.10	All	
15.3.10.5	Males	
15.3.10.10	Females	
15.3.10.15	Transgender	
15.3.10.20	<25	
15.3.10.25	25+	
	B: Number of undocumented migrants who have been tested in the last 12 months and whose result is negative	
15.3.10.1	All	
15.3.10.6	Males	
15.3.10.11	Females	
15.3.10.16	Transgender	
15.3.10.21	<25	
15.3.10.26	25+	
	Numerator (A+B): Number of undocumented migrants who know their HIV status	
15.3.10.2	All	0
15.3.10.7	Males	0
15.3.10.12	Females	0
15.3.10.17	Transgender	0
15.3.10.22	<25	0
15.3.10.27	25+	0
	Denominator: Number of undocumented migrants who responded to the question "Do you know your HIV status from an HIV test?"	
15.3.10.3	All	
15.3.10.8	Males	
15.3.10.13	Females	
15.3.10.18	Transgender	
15.3.10.23	<25	
15.3.10.28	25+	
	Percentage (%): Percentage of undocumented migrants who know their HIV status	
15.3.10.4	All	#DIV/0!
15.3.10.9	Males	#DIV/0!
15.3.10.14	Females	#DIV/0!

15.3.10.19	Transgender	#DIV/0!
15.3.10.24	<25	#DIV/0!
15.3.10.29	25+	#DIV/0!



## HIV testing among sex workers

This form is pre-populated with data reported in the previous data collection round. Previously entered data is shown below each data entry field. Please enter new data if available. If no new data are available, please review and enter the data from the previous dataset in the data entry field.

DDM 202	Question	Response
15.4.0	Does your country collect data on HIV testing among sex workers?	Yes
		No
15.4.0.1	If no, please scroll to the bottom of this form, select form status as 'Complete' and click on 'Save & Exit Form'.	
	This indicator is aligned with GAM 1.4A. Guidance on responding to this question is available <a href="https://www.unaids.org/sites/default/files/media_asset/global-aids-monitoring_en.pdf#page=16">here</a> .	<a href="https://www.unaids.org/sites/default/files/media_asset/global-aids-monitoring_en.pdf#page=16">https://www.unaids.org/sites/default/files/media_asset/global-aids-monitoring_en.pdf#page=16</a>
15.4.1	Data measurement tool / source	Behavioural Surveillance Survey
		Special Study
		Other
15.4.1.1	Other measurement tool / source	
15.4.2	Please specify sampling strategy and location:	
15.4.3	Data Collection Period From:	
15.4.4	Data Collection Period To:	
15.4.5	Additional information related to entered data. e.g. reference to primary data source, methodological concerns:	
15.4.5.1	If available, upload a relevant supporting document by clicking on the icon. Any file format is acceptable, but it must be less than 8MB in size. When it has uploaded successfully, a unique ID will appear in the box.	
15.4.6	Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source:	
15.4.7	Sample size - number of survey respondents	
	<b>A: Number of sex workers who have been tested and whose result is positive</b>	
15.4.8	All	
15.4.13	Males	
15.4.18	Females	
15.4.23	Transgender	
15.4.28	<25	
15.4.33	25+	
	<b>B: Number of sex workers who have been tested in the last 12 months and whose result is negative</b>	
15.4.9	All	
15.4.14	Males	
15.4.19	Females	
15.4.24	Transgender	
15.4.29	<25	
15.4.34	25+	
	<b>Numerator (A+B): Number of sex workers who know their HIV status</b>	
15.4.10	All	0
15.4.15	Males	0
15.4.20	Females	0
15.4.25	Transgender	0
15.4.30	<25	0

15.4.35	25+	0
	Denominator: Number of sex workers who responded to the question "Do you know your HIV status from an HIV test?"	
15.4.11	All	
15.4.16	Males	
15.4.21	Females	
15.4.26	Transgender	
15.4.31	<25	
15.4.36	25+	
	Percentage (%): Percentage of sex workers who know their HIV status	
15.4.12	All	#DIV/0!
15.4.17	Males	#DIV/0!
15.4.22	Females	#DIV/0!
15.4.27	Transgender	#DIV/0!
15.4.32	<25	#DIV/0!
15.4.37	25+	#DIV/0!

HIV testing among people in prisons and other closed settings

This form is pre-populated with data reported in the previous data collection round. Previously entered data is shown below each data entry field. Please enter new data if available. If no new data are available, please review and enter the data from the previous dataset in the data entry field.

DDM 2024	Question	Response
15.5.0	Does your country collect data on HIV testing among people in prisons and other closed settings?	Yes
		No
15.5.0.1	If no, please scroll to the bottom of this form, select form status as 'Complete' and click on 'Save & Exit Form'.	
15.5.1	Data measurement tool / source	Behavioural Surveillance Survey
		Special Study
		Other
15.5.1.1	Other measurement tool / source	
15.5.2	Please specify sampling strategy and location:	
15.5.3	Data Collection Period From:	
15.5.4	Data Collection Period To:	
15.5.5	Additional information related to entered data. e.g. reference to primary data source, methodological concerns:	
15.5.5.1	If available, upload a relevant supporting document by clicking on the icon. Any standard file format is acceptable, but it must be less than 8MB in size. When it has uploaded successfully, a unique ID will appear in the box.	
15.5.6	Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source:	
15.5.7	Sample size - number of survey respondents	
15.5.8	Please provide disaggregations by sex, transgender status and age if available.	
	A. Number of prisoners who have been tested and whose result is positive	
15.5.8	All	
15.5.8.5	Males	
15.5.8.10	Females	
15.5.8.15	Transgender	
15.5.8.20	<25	
15.5.8.25	25+	
	B: Number of prisoners who have been tested in the last 12 months and whose result is negative	
15.5.8.1	All	
15.5.8.6	Males	
15.5.8.11	Females	
15.5.8.16	Transgender	
15.5.8.21	<25	
15.5.8.26	25+	
	Numerator (A+B): Number of prisoners who know their HIV status	
15.5.8.2	All	0
15.5.8.7	Males	0
15.5.8.12	Females	0
15.5.8.17	Transgender	0
15.5.8.22	<25	0
15.5.8.27	25+	0
	Denominator: Number of prisoners who responded to the question "Do you know your HIV status from an HIV test?"	
15.5.8.3	All	

15.5.8.8	Males	
15.5.8.13	Females	
15.5.8.18	Transgender	
15.5.8.23	<25	
15.5.8.28	25+	
	Percentage (%): Percentage of prisoners who know their HIV status	
15.5.8.4	All	#DIV/0!
15.5.8.9	Males	#DIV/0!
15.5.8.14	Females	#DIV/0!
15.5.8.19	Transgender	#DIV/0!
15.5.8.24	<25	#DIV/0!
15.5.8.29	25+	#DIV/0!

HIV testing among transgender people

This form is pre-populated with data reported in the previous data collection round. Previously entered data is shown below each data entry field. Please enter new data if available. If no new data are available, please review and enter the data from the previous dataset in the data entry field.

DDM 2024	Question	Response
15.6.0	Does your country collect data on HIV testing among transgender people?	Yes
		No
15.6.0.1	If no, please scroll to the bottom of this form, select form status as 'Complete' and click on 'Save & Exit Form'.	
	This indicator is aligned with GAM 1.4D. Guidance on responding to this question is available here.	<a href="https://www.unaids.org/sites/default/files/media_asset/global-aids-monitoring_en.pdf#page=16">https://www.unaids.org/sites/default/files/media_asset/global-aids-monitoring_en.pdf#page=16</a>
15.6.1	Data measurement tool / source	Behavioural Surveillance Survey
		Special Study
		Other
15.6.1.1	Other measurement tool / source	
15.6.2	Please specify sampling strategy and location:	
15.6.3	Data Collection Period From:	
15.6.4	Data Collection Period To:	
15.6.5	Additional information related to entered data. e.g. reference to primary data source, methodological concerns:	
15.6.5.1	If available, upload a relevant supporting document by clicking on the icon. Any standard file format is acceptable, but it must be less than 8MB in size. When it has uploaded successfully, a unique ID will appear in the box.	
15.6.6	Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source:	
15.6.7	Sample size - number of survey respondents	
15.6.8	Please provide disaggregations by gender and age if available.	
	A: Number of transgender people who have been tested and whose result is positive	
15.6.8	All	
15.6.8.5	Transman	
15.6.8.10	Transwoman	
15.6.8.15	Other	
15.6.8.20	<25	
15.6.8.25	25+	
	B: Number of transgender people who have been tested in the last 12 months and whose result is negative	
15.6.8.1	All	
15.6.8.6	Transman	
15.6.8.11	Transwoman	
15.6.8.16	Other	
15.6.8.21	<25	
15.6.8.26	25+	
	Numerator (A+B): Number of transgender people who know their HIV status	
15.6.8.2	All	0
15.6.8.7	Transman	0
15.6.8.12	Transwoman	0
15.6.8.17	Other	0
15.6.8.22	<25	0
15.6.8.27	25+	0

	Denominator: Number of transgender people who responded to the question "Do you know your HIV status from an HIV test?"	
15.6.8.3	All	
15.6.8.8	Transman	
15.6.8.13	Transwoman	
15.6.8.18	Other	
15.6.8.23	<25	
15.6.8.28	25+	
	Percentage (%): Percentage of transgender people who know their HIV status	
15.6.8.4	All	#DIV/0!
15.6.8.9	Transman	#DIV/0!
15.6.8.14	Transwoman	#DIV/0!
15.6.8.19	Other	#DIV/0!
15.6.8.24	<25	#DIV/0!
15.6.8.29	25+	#DIV/0!
15.7	Any further comments?	

LINKAGE TO CARE

This form is pre-populated with data reported in the previous data collection round. Previously entered data is shown below each data entry field. Please enter new data if available. If no new data are available, please review and enter the data from the previous dataset in the data entry field.

DDM 2024	Question	Response
16.1	Does your country have a standard or recommendation on when linkage to care should take place following an HIV diagnosis?	
		Same day of diagnosis
		Within one week
		Within 30 days
		Within 3 months
		Other (please specify)
		No standard or recommendation
16.1.1	Please specify:	
16.1.2	If available, upload a relevant supporting document by clicking on the icon. Any standard file format is acceptable, but it must be less than 8MB in size. When it has uploaded successfully, a unique ID will appear in the box.	
16.2	How is linkage to care calculated for facility-level testing in your country?	
		Time between HIV diagnosis date and first clinic attendance date
		Time between HIV diagnosis date and first CD4 count or viral load date
		Time between HIV diagnosis date and HIV treatment start date
		Other (please specify)
		Linkage to care not calculated for facility-level HIV testing
16.2.1	Please specify:	
16.3	How is linkage to care calculated for community-level HIV testing services in your country?	
		Time between HIV reactive test date and confirmatory test
		Time between HIV reactive test date and first clinic attendance date
		Time between HIV reactive test date and first CD4 count or viral load date
		Time between HIV reactive test date and HIV treatment start date
		Time between confirmatory test date and first clinic attendance date
		Time between confirmatory test date and first CD4 count or viral load date
		Time between confirmatory test date and HIV treatment start date
		Other (please specify)
		Linkage to care not calculated for community-level HIV testing
16.3.1	Please specify:	
	The number and proportion of those newly diagnosed in the calendar year linked to care within three months	

16.4	Are data available?	Yes
		No
16.4.1	Data measurement tool / source	HTS programme registers, log books and reporting forms
		Other
16.4.1.1	Other measurement tool / source	
16.4.2	Data Collection Period From:	
16.4.3	Data Collection Period To:	
16.4.4	Additional information related to entered data. e.g. reference to primary data source, methodological concerns:	
16.4.4.1	If available, upload a relevant supporting document by clicking on the icon. Any standard file format is acceptable, but it must be less than 8MB in size. When it has uploaded successfully, a unique ID will appear in the box.	
16.4.5	Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source:	
16.4.6	Please provide disaggregations by testing modality if available.	
	<b>Numerator: Number of those newly diagnosed in the calendar year linked to care within three months</b>	
16.4.6	Overall	
16.4.6.3	All facility-level testing	
16.4.6.6	All community-level HTS reporting	
	<b>Denominator: Number of new diagnoses in the calendar year</b>	
16.4.6.1	Overall	
16.4.6.4	All facility-level testing	
16.4.6.7	All community-level HTS reporting	
	<b>Percentage (%): Proportion of those newly diagnosed in the calendar year promptly linked to care within three months</b>	
16.4.6.2	Overall	
16.4.6.5	All facility-level testing	
16.4.6.8	All community-level HTS reporting	
16.5	Any further comments?	





**CONTINUUM OF CARE FOR ALL PEOPLE LIVING WITH HIV**

This form is pre-populated with data reported in the previous data collection round. Previously entered data is shown below each data entry field. Please enter new data if available. If no new data are available, please review and enter the data from the previous dataset in the data entry field.

DDM 2024	Question	Response
18.1	Definitions for each of the four stages in the continuum	
	Stage 1: Total estimated number of people living with HIV in the country	
	The total estimated number should be based on an empirical modelling approach, using the ECDC HIV Modelling Tool, Spectrum or any other empirical estimate. The estimate should include diagnosed and undiagnosed people.	
	Stage 2: Number/percentage of above (estimated number of people living with HIV in the country) who are living with diagnosed HIV.	
	The number should include all new HIV or AIDS diagnoses. It should also include those people who are in care and those who have not been linked to care.	
	Stage 3: Number/percentage of above (estimated number of people living with HIV in the country, who have been diagnosed) who are currently on antiretroviral treatment.	
	Number with at least one record of ART (prescribed or, ideally, dispensed) by year end, regardless of treatment eligibility criteria. ART is defined as any ART regimen since diagnosis, regardless of the number of antiretroviral drugs.	
	Stage 4: Number/percentage of above (estimated number of people living with HIV in the country, who have been diagnosed, who are currently on antiretroviral treatment) who had VL ≤200 copies/ml at last visit (virally suppressed)	
	Number on ART whose most recent HIV RNA measurement at year end was <200 copies/ml, or below the level of detection of the assay.	
	Where possible, deaths and out-migration should be excluded from reported data.	
	Further detail on the definition of the continuum care can be found in this paper from ECDC	<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5603982/">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5603982/</a>
	All people living with HIV	
18.2	For which of the stages can you provide continuum of care data for all people living with HIV?	Stage 1: What is the total estimated number of people living with HIV in your country?
		Stage 2: What is the number of people living with HIV who have been diagnosed?
		Stage 3: What is the number of people living with HIV who are currently on ART?
		Stage 4: What is the number of people living with HIV who had VL ≤200 copies/ml at their last visit?
		No data available
	Guidance for all indicators: If there are data with unknown age or sex, the age and sex distribution of the cases that are known should be applied to the cases with missing data.	
	Stage 1: What is the total estimated number of people living with HIV in your country?	
18.3	Data measurement tool / source	ECDC modelling tool
		SPECTRUM
		Other modelling tool or estimate
18.3.1	Other modelling tool or estimate	
18.4	End date of the reporting period	
18.5	Were you able to exclude the following?	
18.5	Deaths	Yes
		No

		Partially
		Don't know
18.5.1	Out-migration	Yes
		No
		Partially
		Don't know
18.5.2	Previous positives (people who have been previously diagnosed with HIV prior to arrival to your country)	Yes
		No
		Partially
		Don't know
18.6	How do you deal with 'lost to follow up' cases when reporting this stage of the continuum of care?	Exclude from data
		Partially exclude
		Include
		Other (please specify)
18.6.1	Other (please specify):	
18.7	Estimate of all people living with HIV	
18.7	All	
18.7.3	Males 15+	
18.7.6	Females 15+	
18.7.9	Trans men 15+	
18.7.12	Trans women 15+	
18.7.1	Estimate of all people living with HIV: Lower bound	
18.7.1	All	
18.7.4	Males 15+	
18.7.7	Females 15+	
18.7.10	Trans men 15+	
18.7.13	Trans women 15+	
18.7.2	Estimate of all people living with HIV: Upper bound	
18.7.2	All	
18.7.5	Males 15+	
18.7.8	Females 15+	
18.7.11	Trans men 15+	
18.7.14	Trans women 15+	
	Stage 2: What is the number of people living with HIV who have been diagnosed?	
18.8	Data measurement tool / source	Cohort data
		Surveillance data
18.8.1		Other data source
18.8.1	Other measurement tool / source	
18.9	End date of the reporting period	
18.10	Were you able to exclude the following?	
18.10.1	Deaths	Yes
		No
		Partially
		Don't know
18.10.2	Out-migration	Yes

		No
		Partially
		Don't know
18.10.3	Previous positives (people who have been previously diagnosed with HIV prior to arrival to your country)	Yes
		No
		Partially
		Don't know
18.11	How do you deal with 'lost to follow up' cases when reporting this stage of the continuum of care?	Exclude from data
		Partially exclude
		Include
		Other (please specify)
18.11.1	Please specify:	
18.12	People living with HIV who have been diagnosed	
18.12	All	
18.12.1	Males 15+	
18.12.2	Females 15+	
18.12.3	Trans men 15+	
18.12.4	Trans women 15+	
	Stage 3: What is the number of people living with HIV who are currently on ART?	
18.13	Data measurement tool / source	Cohort data
		Surveillance data
		Other data soure
18.13.1	Other measurement tool / source	
18.14	End date of the reporting period	
18.15	Were you able to exclude the following?	
18.15.1	Deaths	Yes
		No
		Partially
		Don't know
18.15.2	Out-migration	Yes
		No
		Partially
		Don't know
18.15.3	Previous positives (people who have been previously diagnosed with HIV prior to arrival to your country)	Yes
		No
		Partially
		Don't know
18.16	How do you deal with 'lost to follow up' cases when reporting this stage of the continuum of care?	Exclude from data
		Partially exclude
		Include
18.16.1		Other (please specify)

<b>18.17</b>		
	<b>People living with HIV who are receiving ART</b>	
<b>18.17</b>	All	
<b>18.17.4</b>	Males 15+	
<b>18.17.7</b>	Females 15+	
<b>18.17.10</b>	Trans men 15+	
<b>18.17.13</b>	Trans women 15+	
	<b>People living with HIV who are initiating ART</b>	
<b>18.17.2</b>	All	
<b>18.17.5</b>	Males 15+	
<b>18.17.8</b>	Females 15+	
<b>18.17.11</b>	Trans men 15+	
<b>18.17.14</b>	Trans women 15+	
	<b>People reinitiating antiretroviral treatment (among those initiating antiretroviral treatment)</b>	
<b>18.17.3</b>	All	
<b>18.17.6</b>	Males 15+	
<b>18.17.9</b>	Females 15+	
<b>18.17.12</b>	Trans men 15+	
<b>18.17.15</b>	Trans women 15+	
	<b>Stage 4: What is the number of people living with HIV who had VL ≤200 copies/ml at their last visit?</b>	
	<p>Special guidance for stage 4 data: Viral suppression is defined as &lt;1000 copies/mL. For countries with other thresholds (such as undetectable, &lt;50 copies/mL or &lt;400 copies/mL), ECDC recommends that countries adjust for lower threshold detection. This adjustment will be done automatically in Spectrum, if required based on the entered threshold. Countries who use survey data for stage 4 data should extrapolate from the survey results to obtain the total number of people suppressed among all people living with HIV. If viral suppression data from routine programme or case surveillance data are reported as partially accessible (typically testing coverage among people on treatment between 50% or more), the third 95 estimate (the number of people suppressed among those tested) should be multiplied by the number on treatment to obtain the total number of people virally suppressed among all people living with HIV. All countries should report the total number of people tested for viral load suppression regardless of testing coverage or data source. Please see GAM guidance and FAQs for more details.</p>	<a href="http://www.unaids.org/sites/default/files/media_asset/global-aids-monitoring_en.pdf#page=48">http://www.unaids.org/sites/default/files/media_asset/global-aids-monitoring_en.pdf#page=48</a>
<b>18.18</b>	Data measurement tool / source	Cohort data
		Surveillance data
		Other data source
<b>18.18.1</b>	Other measurement tool / source	
<b>18.19</b>	End date of the reporting period	
<b>18.20</b>	<b>Were you able to exclude the following?</b>	
<b>18.20.1</b>	Deaths	Yes
		No
		Partially
		Don't know
<b>18.20.2</b>	Out-migration	Yes
		No
		Partially
		Don't know
<b>18.20.3</b>	<b>Previous positives (people who have been previously diagnosed with HIV prior to arrival to your country)</b>	<b>Yes</b>

		No
		Partially
		Don't know
18.21	How do you deal with 'lost to follow up' cases when reporting this stage of the continuum of care?	Exclude from data
		Partially exclude
		Include
18.21.1		Other (please specify)
18.22		
	People living with HIV on antiretroviral treatment who have suppressed viral load	
18.22	All	
18.22.3	Males 15+	
18.22.6	Females 15+	
18.22.9	Trans men 15+	
18.22.12	Trans women 15+	
	People receiving a routine viral load test among those on antiretroviral treatment	
18.22.1	All	
18.22.4	Males 15+	
18.22.7	Females 15+	
18.22.10	Trans men 15+	
18.22.13	Trans women 15+	
	People who are virally suppressed among those routinely tested for viral load	
18.22.2	All	
18.22.5	Males 15+	
18.22.8	Females 15+	
18.22.11	Trans men 15+	
18.22.14	Trans women 15+	
	Calculated HIV testing and treatment cascade and 95-95-95 percentages	NO RESPONSE REQUIRED
	Percentage (%): People living with HIV who know their HIV status (First 95)	
V1	All	#DIV/0!
18.23	Is this percentage correct?	Yes
		No
18.23.1	Please manually input correct percentage:	
V2	Males 15+	#DIV/0!
18.24	Is this percentage correct?	Yes
		No
18.24.1	Please manually input correct percentage:	
V3	Females 15+	#DIV/0!
18.25	Is this percentage correct?	Yes
		No
18.25.1	Please manually input correct percentage:	
V4	Trans men 15+	#DIV/0!
18.26	Is this percentage correct?	Yes
		No
18.26.1	Please manually input correct percentage:	
V5	Trans women 15+	#DIV/0!
18.27	Is this percentage correct?	Yes
		No

18.27.1	Please manually input correct percentage:	
	Percentage (%): People living with HIV who are on treatment (Target: 91%)	
V6	All	#DIV/0!
18.28	Is this percentage correct?	Yes
		No
18.28.1	Please manually input correct percentage:	
V7	Males 15+	#DIV/0!
18.29	Is this percentage correct?	Yes
		No
18.29.1	Please manually input correct percentage:	
V8	Females 15+	#DIV/0!
18.30	Is this percentage correct?	Yes
		No
18.30.1	Please manually input correct percentage:	
V9	Trans men 15+	#DIV/0!
18.31	Is this percentage correct?	Yes
		No
18.31.1	Please manually input correct percentage:	
V10	Trans women 15+	#DIV/0!
18.32	Is this percentage correct?	Yes
		No
18.32.1	Please manually input correct percentage:	
	Percentage (%): People living with HIV who have a suppressed viral load (Target: 86%)*	
V11	All	#DIV/0!
18.33	Is this percentage correct?	Yes
		No
18.33.1	Please manually input correct percentage:	
V12	Males 15+	#DIV/0!
18.34	Is this percentage correct?	Yes
		No
18.34.1	Please manually input correct percentage:	
V13	Females 15+	#DIV/0!
18.35	Is this percentage correct?	Yes
		No
18.35.1	Please manually input correct percentage:	
V14	Trans men 15+	#DIV/0!
18.36	Is this percentage correct?	Yes
		No
18.36.1	Please manually input correct percentage:	
V15	Trans women 15+	#DIV/0!
18.37	Is this percentage correct?	Yes
		No
18.37.1	Please manually input correct percentage:	
	Percentage (%): People who are on treatment among those who know their HIV status (Second 95)	
V16	All	#DIV/0!
18.38	Is this percentage correct?	Yes
		No
18.38.1	Please manually input correct percentage:	
V17	Males 15+	#DIV/0!

18.39	Is this percentage correct?	Yes
		No
18.39.1	Please manually input correct percentage:	
V18	Females 15+	#DIV/0!
18.40	Is this percentage correct?	Yes
		No
18.40.1	Please manually input correct percentage:	
V19	Trans men 15+	#DIV/0!
18.41	Is this percentage correct?	Yes
		No
18.41.1	Please manually input correct percentage:	
V20	Trans women 15+	#DIV/0!
18.42	Is this percentage correct?	Yes
		No
18.42.1	Please manually input correct percentage:	
	Percentage (%): People on antiretroviral treatment who have a suppressed viral load (Third 95)	
V21	All	#DIV/0!
18.43	Is this percentage correct?	Yes
		No
18.43.1	Please manually input correct percentage:	
V22	Males 15+	#DIV/0!
18.44	Is this percentage correct?	Yes
		No
18.44.1	Please manually input correct percentage:	
V23	Females 15+	#DIV/0!
18.45	Is this percentage correct?	Yes
		No
18.45.1	Please manually input correct percentage:	
V24	Trans men 15+	#DIV/0!
18.46	Is this percentage correct?	Yes
		No
18.46.1	Please manually input correct percentage:	
V25	Trans women 15+	#DIV/0!
18.47	Is this percentage correct?	Yes
		No
18.47.1	Please manually input correct percentage:	
	Percentage (%): People on antiretroviral treatment who have had a viral load test	
V26	All	#DIV/0!
18.48	Is this percentage correct?	Yes
		No
18.48.1	Please manually input correct percentage:	
V27	Males 15+	#DIV/0!
18.49	Is this percentage correct?	Yes
		No
18.49.1	Please manually input correct percentage:	
V28	Females 15+	#DIV/0!
18.50	Is this percentage correct?	Yes
		No
18.50.1	Please manually input correct percentage:	
V29	Trans men 15+	#DIV/0!



18.51	Is this percentage correct?	Yes
		No
18.51.1	Please manually input correct percentage:	
V30	Trans women 15+	#DIV/0!
18.52	Is this percentage correct?	Yes
		No
18.52.1	Please manually input correct percentage:	

CONTINUUM OF CARE FOR MEN WHO HAVE SEX WITH MEN

This form is pre-populated with data reported in the previous data collection round. Previously entered data is shown below each data entry field. Please enter new data if available. If no new data are available, please review and enter the data from the previous dataset in the data entry field.

DDM 2024	Question	Response
	Men who have sex with men	
Q19.2	For which of the stages can you provide continuum of care data for all MSM living with HIV?	Stage 1: What is the total estimated number of MSM living with HIV in your country?
		Stage 2: What is the number of MSM living with HIV who have been diagnosed?
		Stage 3: What is the number of MSM living with HIV who are currently on ART?
		Stage 4: What is the number of MSM living with HIV who had VL ≤200 copies/ml at their last visit?
		No data available
Q19.2.1	What are the barriers to obtaining this data?	Insufficient funding
		No mechanism in place to collect data
		Individuals are not accessing care
		Other (please specify):
	Stage 1: What is the total estimated number of MSM living with HIV in your country?	
Q19.3	Data measurement tool / source	ECDC modelling tool
		SPECTRUM
		Other modelling tool or estimate
Q19.3.1	Other modelling tool or estimate	
Q19.4	End date of the reporting period	
Q19.5	Were you able to exclude the following?	
Q19.5	Deaths	Yes
		No
		Partially
		Don't know
Q19.5.1	Out-migration	Yes
		No
		Partially
		Don't know
Q19.5.2	Previous positives (people who have been previously diagnosed with HIV prior to arrival to your country)	Yes
		No
		Partially
		Don't know
Q19.6	How do you deal with 'lost to follow up' cases when reporting this stage of the continuum of care?	Exclude from data
		Partially exclude
		Include
Q19.6.1		Other (please specify)
Q19.7	Estimate of all MSM living with HIV	
Q19.7.1	Estimate of all MSM living with HIV: Lower bound	
Q19.7.2	Estimate of all MSM living with HIV: Upper bound	
	Stage 2: What is the number of MSM living with HIV who have been diagnosed?	
19.8	Data measurement tool / source	Cohort data
		Surveillance data

		Other data source
Q19.8.1	Other measurement tool / source	
Q19.9	End date of the reporting period	
Q19.10	Were you able to exclude the following?	
Q19.10.1	Deaths	Yes
		No
		Partially
		Don't know
Q19.10.2	Out-migration	Yes
		No
		Partially
		Don't know
Q19.10.3	Previous positives (people who have been previously diagnosed with HIV prior to arrival to your country)	Yes
		No
		Partially
		Don't know
Q19.11	How do you deal with 'lost to follow up' cases when reporting this stage of the continuum of care?	Exclude from data
		Partially exclude
		Include
Q19.11.1		Other (please specify)
Q19.12	MSM living with HIV who know their HIV status	
	Stage 3: What is the number of MSM living with HIV who are currently on ART?	
Q19.13	Data measurement tool / source	Cohort data
		Surveillance data
		Other data source
Q19.13.1	Other measurement tool / source	
Q19.14	End date of the reporting period	
Q19.15	Were you able to exclude the following?	
Q19.15.1	Deaths	Yes
		No
		Partially
		Don't know
Q19.15.2	Out-migration	Yes
		No
		Partially
		Don't know
Q19.15.3	Previous positives (people who have been previously diagnosed with HIV prior to arrival to your country)	Yes
		No
		Partially
		Don't know
Q19.16	How do you deal with 'lost to follow up' cases when reporting this stage of the continuum of care?	Exclude from data
		Partially exclude
		Include

Q19.16.1		Other (please specify)
Q19.17	MSM living with HIV who are receiving ART	
Q19.17.1	MSM living with HIV who are initiating ART	
Q19.17.2	MSM reinitiating antiretroviral treatment (among those initiating antiretroviral treatment)	
	<b>Stage 4: What is the number of MSM living with HIV who had VL ≤200 copies/ml at their last visit?</b>	
Q19.18	Data measurement tool / source	Cohort data
		Surveillance data
		Other data source
Q19.18.1	Other measurement tool / source	
Q19.19	End date of the reporting period	
Q19.20	<b>Were you able to exclude the following?</b>	
Q19.20.1	Deaths	Yes
		No
		Partially
		Don't know
Q19.20.2	Out-migration	Yes
		No
		Partially
		Don't know
Q19.20.3	Previous positives (people who have been previously diagnosed with HIV prior to arrival to your country)	Yes
		No
		Partially
		Don't know
Q19.21	How do you deal with 'lost to follow up' cases when reporting this stage of the continuum of care?	Exclude from data
		Partially exclude
		Include
Q19.21.1		Other (please specify)
Q19.22	MSM living with HIV on antiretroviral treatment who have suppressed viral load	
Q19.22.1	MSM receiving a routine viral load test among those on antiretroviral treatment	
Q19.22.2	MSM who are virally suppressed among those routinely tested for viral load	
	<b>Calculated HIV testing and treatment cascade and 95-95-95 percentages</b>	<b>NO RESPONSE REQUIRED</b>
V1_msm	Percentage (%): MSM living with HIV who know their HIV status (First 95)	#DIV/0!
19.23	Is this percentage correct?	Yes
		No
19.23.1	Please manually input correct percentage:	
V6_msm	Percentage (%): MSM living with HIV who are on treatment (Target: 91%)	#DIV/0!
19.26	Is this percentage correct?	Yes
		No
19.26.1	Please manually input correct percentage:	
V11_msm	Percentage (%): MSM living with HIV who have a suppressed viral load (Target: 86%)*	#DIV/0!
19.29	Is this percentage correct?	Yes
		No
19.29.1	Please manually input correct percentage:	
V16_msm	Percentage (%): MSM who are on treatment among those who know their HIV status (Second 95)	#DIV/0!
19.32	Is this percentage correct?	Yes

		No
19.32.1	Please manually input correct percentage:	
V21_msm	Percentage (%): MSM on antiretroviral treatment who have a suppressed viral load (Third 95)*	#DIV/0!
19.35	Is this percentage correct?	Yes
		No
19.35.1	Please manually input correct percentage:	
v_unknown_msm	Percentage (%): MSM on antiretroviral treatment who have had a viral load test	#DIV/0!
19.38	Is this percentage correct?	Yes
		No
19.38.1	Please manually input correct percentage:	

CONTINUUM OF CARE FOR PEOPLE WHO INJECT DRUGS

This form is pre-populated with data reported in the previous data collection round. Previously entered data is shown below each data entry field. Please enter new data if available. If no new data are available, please review and enter the data from the previous dataset in the data entry field.

DDM 2024	Question	Response
	People who inject drugs	
20.2	For which of the stages can you provide continuum of care data for all PWID living with HIV?	Stage 1: What is the total estimated number of PWID living with HIV in your country?
		Stage 2: What is the number of PWID living with HIV who have been diagnosed?
		Stage 3: What is the number of PWID living with HIV who are currently on ART?
		Stage 4: What is the number of PWID living with HIV who had VL ≤200 copies/ml at their last visit?
No data available		
20.2.1	What are the barriers to obtaining this data?	Insufficient funding
		No mechanism in place to collect data
		Individuals are not accessing care
20.2.1.1		Other (please specify):
	Stage 1: What is the total estimated number of PWID living with HIV in your country?	
20.3	Data measurement tool / source	ECDC modelling tool
		SPECTRUM
		Other modelling tool or estimate
20.3.1	Other modelling tool or estimate	
20.4	End date of the reporting period	
20.5	Were you able to exclude the following?	
20.5	Deaths	Yes
		No
		Partially
		Don't know
20.5.1	Out-migration	Yes
		No
		Partially
		Don't know
Q20.5.2	Previous positives (people who have been previously diagnosed with HIV prior to arrival to your country)	Yes
		No
		Partially
		Don't know
20.6	How do you deal with 'lost to follow up' cases when reporting this stage of the continuum of care?	Exclude from data
		Partially exclude
		Include
20.6.1		Other (please specify)
20,7	Estimate of all PWID living with HIV	

20.7.1	Estimate of all PWID living with HIV: Lower bound	
20.7.2	Estimate of all PWID living with HIV: Upper bound	
	Stage 2: What is the number of PWID living with HIV who have been diagnosed?	
20.8	Data measurement tool / source	Cohort data
		Surveillance data
		Other data source
20.8.1	Other measurement tool / source	
20.9	End date of the reporting period	
20.1	Were you able to exclude the following?	
20.10.1	Deaths	Yes
		No
		Partially
		Don't know
20.10.2	Out-migration	Yes
		No
		Partially
		Don't know
Q20.10.3	Previous positives (people who have been previously diagnosed with HIV prior to arrival to your country)	Yes
		No
		Partially
		Don't know
20.11	How do you deal with 'lost to follow up' cases when reporting this stage of the continuum of care?	Exclude from data
		Partially exclude
		Include
20.11.1		Other (please specify)
20,12	PWID living with HIV who know their HIV status	
	Stage 3: What is the number of PWID living with HIV who are currently on ART?	
20.13	Data measurement tool / source	Cohort data
		Surveillance data
		Other data source
20.13.1	Other measurement tool / source	
20.14	End date of the reporting period	
20.15	Were you able to exclude the following?	
20.15.1	Deaths	Yes
		No
		Partially
		Don't know
20.15.2	Out-migration	Yes
		No
		Partially
		Don't know
Q20.15.3	Previous positives (people who have been previously diagnosed with HIV prior to arrival to your country)	Yes
		No

		Partially
		Don't know
20.16	How do you deal with 'lost to follow up' cases when reporting this stage of the continuum of care?	Exclude from data
		Partially exclude
		Include
20.16.1		Other (please specify)
20.17	PWID living with HIV who are receiving ART	
20.17.1	PWID living with HIV who are initiating ART	
20.17.2	PWID reinitiating antiretroviral treatment (among those initiating antiretroviral treatment)	
	Stage 4: What is the number of PWID living with HIV who had VL ≤200 copies/ml at their last visit?	
20.18	Data measurement tool / source	Cohort data
		Surveillance data
		Other data source
20.18.1	Other measurement tool / source	
20.19	End date of the reporting period	
20.2	Were you able to exclude the following?	
20.20.1	Deaths	Yes
		No
		Partially
		Don't know
20.20.2	Out-migration	Yes
		No
		Partially
		Don't know
Q20.20.3	Previous positives (people who have been previously diagnosed with HIV prior to arrival to your country)	Yes
		No
		Partially
		Don't know
20.21	How do you deal with 'lost to follow up' cases when reporting this stage of the continuum of care?	Exclude from data
		Partially exclude
		Include
20.21.1		Other (please specify)
20.22	PWID living with HIV on antiretroviral treatment who have suppressed viral load	
20.22.1	PWID receiving a routine viral load test among those on antiretroviral treatment	
20.22.2	PWID who are virally suppressed among those routinely tested for viral load	
	Calculated HIV testing and treatment cascade and 95-95-95 percentages	
V1_pwid	Percentage (%): PWID living with HIV who know their HIV status (First 95)	#DIV/0!
20.23	Is this percentage correct?	Yes
		No
20.23.1	Please manually input correct percentage:	
V6_pwid	Percentage (%): PWID living with HIV who are on treatment (Target: 91%)	#DIV/0!



20.24	Is this percentage correct?	Yes
		No
20.24.1	Please manually input correct percentage:	
V11_pwid	Percentage (%): PWID living with HIV who have a suppressed viral load (Target: 86%)*	#DIV/0!
20.25	Is this percentage correct?	Yes
		No
20.25.1	Please manually input correct percentage:	
V16_pwid	Percentage (%): PWID who are on treatment among those who know their HIV status (Second 95)	#DIV/0!
20.26	Is this percentage correct?	Yes
		No
20.26.1	Please manually input correct percentage:	
V21_pwid	Percentage (%): PWID on antiretroviral treatment who have a suppressed viral load (Third 95)*	#DIV/0!
20.27	Is this percentage correct?	Yes
		No
20.27.1	Please manually input correct percentage:	
v_unknown_pwid	Percentage (%): PWID on antiretroviral treatment who have had a viral load test	#DIV/0!
20.28	Is this percentage correct?	Yes
		No
20.28.1	Please manually input correct percentage:	

CONTINUUM OF CARE FOR MIGRANTS (persons born abroad)

This form is pre-populated with data reported in the previous data collection round. Previously entered data is shown below each data entry field. Please enter new data if available. If no new data are available, please review and enter the data from the previous dataset in the data entry field.

DDM 2024	Question	Response
	Migrants (persons born abroad)	
21.2	For which of the stages can you provide continuum of care data for all migrants living with HIV?	Stage 1: What is the total estimated number of migrants living with HIV in your country?
		Stage 2: What is the number of migrants living with HIV who have been diagnosed?
		Stage 3: What is the number of migrants living with HIV who are currently on ART?
		Stage 4: What is the number of migrants living with HIV who had VL ≤200 copies/ml at their last visit?
		No data available
21.2.1	What are the barriers to obtaining this data?	Insufficient funding
		No mechanism in place to collect data
		Individuals are not accessing care
		Other (please specify):
	Stage 1: What is the total estimated number of migrants living with HIV in your country?	
21.3	Data measurement tool / source	ECDC modelling tool
		SPECTRUM
		Other modelling tool or estimate
21.3.1	Other modelling tool or estimate	
21.4	End date of the reporting period	
21.5	Were you able to exclude the following?	
21.5	Deaths	Yes
		No
		Partially
		Don't know
21.5.1	Out-migration	Yes
		No
		Partially
		Don't know
Q21.5.2	Previous positives (people who have been previously diagnosed with HIV prior to arrival to your country)	Yes
		No
		Partially
		Don't know
21.6	How do you deal with 'lost to follow up' cases when reporting this stage of the continuum of care?	Exclude from data
		Partially exclude
		Include
21.6.1		Other (please specify)
21.7	Estimate of all migrants living with HIV	

21.7.1	Estimate of all migrants living with HIV: Lower bound	
21.7.2	Estimate of all migrants living with HIV: Upper bound	
	<b>Stage 2: What is the number of migrants living with HIV who have been diagnosed?</b>	
21.8	Data measurement tool / source	Cohort data
		Surveillance data
		Other data source
21.8.1	Other measurement tool / source	
21.9	End date of the reporting period	
21.1	<b>Were you able to exclude the following?</b>	
21.10.1	Deaths	Yes
		No
		Partially
		Don't know
21.10.2	Out-migration	Yes
		No
		Partially
		Don't know
Q21.10.3	<b>Previous positives (people who have been previously diagnosed with HIV prior to arrival to your country)</b>	
		<b>Yes</b>
		<b>No</b>
		<b>Partially</b>
		<b>Don't know</b>
21.11	How do you deal with 'lost to follow up' cases when reporting this stage of the continuum of care?	Exclude from data
		Partially exclude
		Include
21.11.1		Other (please specify)
21.12	Migrants living with HIV who know their HIV status	
	<b>Stage 3: What is the number of migrants living with HIV who are currently on ART?</b>	
21.13	Data measurement tool / source	Cohort data
		Surveillance data
		Other data source
21.13.1	Other measurement tool / source	
21.14	End date of the reporting period	
21.15	<b>Were you able to exclude the following?</b>	
21.15.1	Deaths	Yes
		No
		Partially
		Don't know
21.15.2	Out-migration	Yes
		No
		Partially
		Don't know
Q21.15.3	<b>Previous positives (people who have been previously diagnosed with HIV prior to arrival to your country)</b>	
		<b>Yes</b>
		<b>No</b>

		Partially
		Don't know
21.16	How do you deal with 'lost to follow up' cases when reporting this stage of the continuum of care?	Exclude from data
		Partially exclude
		Include
21.16.1		Other (please specify)
21.17	Migrants living with HIV who are receiving ART	
21.17.1	Migrants living with HIV who are initiating ART	
21.17.2	Migrants reinitiating antiretroviral treatment (among those initiating antiretroviral treatment)	
	Stage 4: What is the number of migrants living with HIV who had VL ≤200 copies/ml at their last visit?	
21.18	Data measurement tool / source	Cohort data
		Surveillance data
		Other data source
21.18.1	Other measurement tool / source	
21.19	End date of the reporting period	
21.2	Were you able to exclude the following?	
21.20.1	Deaths	Yes
		No
		Partially
		Don't know
21.20.2	Out-migration	Yes
		No
		Partially
		Don't know
Q21.20.3	Previous positives (people who have been previously diagnosed with HIV prior to arrival to your country)	Yes
		No
		Partially
		Don't know
21.21	How do you deal with 'lost to follow up' cases when reporting this stage of the continuum of care?	Exclude from data
		Partially exclude
		Include
21.21.1		Other (please specify)
21.22	Migrants living with HIV on antiretroviral treatment who have suppressed viral load	
21.22.1	Migrants receiving a routine viral load test among those on antiretroviral treatment	
21.22.2	Migrants who are virally suppressed among those routinely tested for viral load	
	Calculated HIV testing and treatment cascade and 95-95-95 percentages	NO RESPONSE REQUIRED
V1_migrant	Percentage (%): Migrants living with HIV who know their HIV status (First 95)	#DIV/0!
21.23	Is this percentage correct?	Yes
		No
21.23.1	Please manually input correct percentage:	
V6_migrant	Percentage (%): Migrants living with HIV who are on treatment (Target: 91%)	#DIV/0!
21.24	Is this percentage correct?	Yes

		No
21.24.1	Please manually input correct percentage:	
V11_migrat	Percentage (%): Migrants living with HIV who have a suppressed viral load (Target: 86%)*	#DIV/0!
21.25	Is this percentage correct?	Yes
		No
21.25.1	Please manually input correct percentage:	
V16_migrat	Percentage (%): Migrants who are on treatment among those who know their HIV status (Second 95)	#DIV/0!
21.26	Is this percentage correct?	Yes
		No
21.26.1	Please manually input correct percentage:	
V21_migrat	Percentage (%): Migrants on antiretroviral treatment who have a suppressed viral load (Third 95)*	#DIV/0!
21.27	Is this percentage correct?	Yes
		No
21.27.1	Please manually input correct percentage:	
v_unknown	Percentage (%): Migrants on antiretroviral treatment who have had a viral load test	#DIV/0!
21.28	Is this percentage correct?	Yes
		No
21.28.1	Please manually input correct percentage:	

CONTINUUM OF CARE FOR SEX WORKERS

This form is pre-populated with data reported in the previous data collection round. Previously entered data is shown below each data entry field. Please enter new data if available. If no new data are available, please review and enter the data from the previous dataset in the data entry field.

DDM 2024	Question	Response
	Sex workers	
22.2	For which of the stages can you provide continuum of care data for all sex workers living with HIV?	Stage 1: What is the total estimated number of sex workers living with HIV in your country?
		Stage 2: What is the number of sex workers living with HIV who have been diagnosed?
		Stage 3: What is the number of sex workers living with HIV who are currently on ART?
		Stage 4: What is the number of sex workers living with HIV who had VL ≤200 copies/ml at their last visit?
		No data available
22.2.1	What are the barriers to obtaining this data?	Insufficient funding
		No mechanism in place to collect data
		Individuals are not accessing care
		Other (please specify):
	Stage 1: What is the total estimated number of sex workers living with HIV in your country?	
22.3	Data measurement tool / source	ECDC modelling tool
		SPECTRUM
		Other modelling tool or estimate
22.3.1	Other modelling tool or estimate	
22.4	End date of the reporting period	
22.5	Were you able to exclude the following?	
22.5	Deaths	Yes
		No
		Partially
		Don't know
22.5.1	Out-migration	Yes
		No
		Partially
		Don't know
Q22.5.2	Previous positives (people who have been previously diagnosed with HIV prior to arrival to your country)	Yes
		No
		Partially
		Don't know
22.6	How do you deal with 'lost to follow up' cases when reporting this stage of the continuum of care?	Exclude from data
		Partially exclude
		Include
22.6.1		Other (please specify)

22.7	Estimate of all sex workers living with HIV	
22.7.1	Estimate of all sex workers living with HIV: Lower bound	
22.7.2	Estimate of all sex workers living with HIV: Upper bound	
	Stage 2: What is the number of sex workers living with HIV who have been diagnosed?	
22.8	Data measurement tool / source	Cohort data
		Surveillance data
		Other data source
22.8.1	Other measurement tool / source	
22.9	End date of the reporting period	
22.1	Were you able to exclude the following?	
22.10.1	Deaths	Yes
		No
		Partially
		Don't know
22.10.2	Out-migration	Yes
		No
		Partially
		Don't know
Q22.10.3	Previous positives (people who have been previously diagnosed with HIV prior to arrival to your country)	Yes
		No
		Partially
		Don't know
22.11	How do you deal with 'lost to follow up' cases when reporting this stage of the continuum of care?	Exclude from data
		Partially exclude
		Include
22.11.1		Other (please specify)
22.12	Sex workers living with HIV who know their HIV status	
	Stage 3: What is the number of sex workers living with HIV who are currently on ART?	
22.13	Data measurement tool / source	Cohort data
		Surveillance data
		Other data source
22.13.1	Other measurement tool / source	
22.14	End date of the reporting period	
22.15	Were you able to exclude the following?	
22.15.1	Deaths	Yes
		No
		Partially
		Don't know
22.15.2	Out-migration	Yes
		No
		Partially
		Don't know
Q22.15.3	Previous positives (people who have been previously diagnosed with HIV prior to arrival to your country)	Yes

		No
		Partially
		Don't know
22.16	How do you deal with 'lost to follow up' cases when reporting this stage of the continuum of care?	Exclude from data
		Partially exclude
		Include
22.16.1		Other (please specify)
22.17	Sex workers living with HIV who are receiving ART	
22.17.1	Sex workers living with HIV who are initiating ART	
22.17.2	Sex workers reinitiating antiretroviral treatment (among those initiating antiretroviral treatment)	
	Stage 4: What is the number of sex workers living with HIV who had VL ≤200 copies/ml at their last visit?	
22.18	Data measurement tool / source	Cohort data
		Surveillance data
		Other data source
22.18.1	Other measurement tool / source	
22.19	End date of the reporting period	
22.2	Were you able to exclude the following?	
22.20.1	Deaths	Yes
		No
		Partially
		Don't know
22.20.2	Out-migration	Yes
		No
		Partially
		Don't know
Q22.20.3	Previous positives (people who have been previously diagnosed with HIV prior to arrival to your country)	Yes
		No
		Partially
		Don't know
22.21	How do you deal with 'lost to follow up' cases when reporting this stage of the continuum of care?	Exclude from data
		Partially exclude
		Include
21.21.1		Other (please specify)
22.22	Sex workers living with HIV on antiretroviral treatment who have suppressed viral load	
22.22.1	Sex workers receiving a routine viral load test among those on antiretroviral treatment	
22.22.2	Sex workers who are virally suppressed among those routinely tested for viral load	
	Calculated HIV testing and treatment cascade and 95-95-95 percentages	NO RESPONSE REQUIRED
V1_sw	Percentage (%): Sex workers living with HIV who know their HIV status (First 95)	#DIV/0!
22.23	Is this percentage correct?	Yes
		No
22.23.1	Please manually input correct percentage:	
V6_sw	Percentage (%): Sex workers living with HIV who are on treatment (Target: 91%)	#DIV/0!
22.24	Is this percentage correct?	Yes
		No



22.24.1	Please manually input correct percentage:	
V11_sw	Percentage (%): Sex workers living with HIV who have a suppressed viral load (Target: 86%)*	#DIV/0!
22.25	Is this percentage correct?	Yes
		No
22.25.1	Please manually input correct percentage:	
V16_sw	Percentage (%): Sex workers who are on treatment among those who know their HIV status (Second 95)	#DIV/0!
22.26	Is this percentage correct?	Yes
		No
22.26.1	Please manually input correct percentage:	
V21_sw	Percentage (%): Sex workers on antiretroviral treatment who have a suppressed viral load (Third 95)*	#DIV/0!
22.27	Is this percentage correct?	Yes
		No
22.27.1	Please manually input correct percentage:	
v_unknown	Percentage (%): Sex workers on antiretroviral treatment who have had a viral load test	#DIV/0!
22.28	Is this percentage correct?	Yes
		No
22.28.1	Please manually input correct percentage:	

CONTINUUM OF CARE FOR PEPOLE IN PRISONS AND OTHER CLOSED SETTINGS

This form is pre-populated with data reported in the previous data collection round. Previously entered data is shown below each data entry field. Please enter new data if available. If no new data are available, please review and enter the data from the previous dataset in the data entry field.

DDM 2024	Question	Response
	Prisoners	
23.2	For which of the stages can you provide continuum of care data for all prisoners living with HIV?	Stage 1: What is the total estimated number of prisoners living with HIV in your country?
		Stage 2: What is the number of prisoners living with HIV who have been diagnosed?
		Stage 3: What is the number of prisoners living with HIV who are currently on ART?
		Stage 4: What is the number of prisoners living with HIV who had VL ≤200 copies/ml at their last visit?
		No data available
23.2.1	What are the barriers to obtaining this data?	Insufficient funding
		No mechanism in place to collect data
		Individuals are not accessing care
		Other (please specify):
	Stage 1: What is the total estimated number of prisoners living with HIV in your country?	
23.3	Data measurement tool / source	ECDC modelling tool
		SPECTRUM
		Other modelling tool or estimate
23.3.1	Other modelling tool or estimate	
23.4	End date of the reporting period	
23.5	Were you able to exclude the following?	
23.5	Deaths	Yes
		No
		Partially
		Don't know
23.5.1	Out-migration	Yes
		No
		Partially
		Don't know
Q23.5.2	Previous positives (people who have been previously diagnosed with HIV prior to arrival to your country)	Yes
		No
		Partially
		Don't know
23.6	How do you deal with 'lost to follow up' cases when reporting this stage of the continuum of care?	Exclude from data
		Partially exclude
		Include
23.6.1		Other (please specify)
23.7	Estimate of all prisoners living with HIV	
23.7.1	Estimate of all prisoners living with HIV: Lower bound	

23.7.2	Estimate of all prisoners living with HIV: Upper bound	
	<b>Stage 2: What is the number of prisoners living with HIV who have been diagnosed?</b>	
23.8	Data measurement tool / source	Cohort data
		Surveillance data
		Other data source
23.8.1	Other measurement tool / source	
23.9	End date of the reporting period	
23.1	<b>Were you able to exclude the following?</b>	
23.10.1	Deaths	Yes
		No
		Partially
		Don't know
23.10.2	Out-migration	Yes
		No
		Partially
		Don't know
Q23.10.3	<b>Previous positives (people who have been previously diagnosed with HIV prior to arrival to your country)</b>	
		<b>Yes</b>
		<b>No</b>
		<b>Partially</b>
		<b>Don't know</b>
23.11	How do you deal with 'lost to follow up' cases when reporting this stage of the continuum of care?	Exclude from data
		Partially exclude
		Include
23.11.1		Other (please specify)
23.12	Prisoners living with HIV who know their HIV status	
	<b>Stage 3: What is the number of prisoners living with HIV who are currently on ART?</b>	
23.13	Data measurement tool / source	Cohort data
		Surveillance data
		Other data soure
23.13.1	Other measurement tool / source	
23.14	End date of the reporting period	
23.15	<b>Were you able to exclude the following?</b>	
23.15.1	Deaths	Yes
		No
		Partially
		Don't know
23.15.2	Out-migration	Yes
		No
		Partially
		Don't know
Q23.15.3	<b>Previous positives (people who have been previously diagnosed with HIV prior to arrival to your country)</b>	
		<b>Yes</b>
		<b>No</b>
		<b>Partially</b>
		<b>Don't know</b>

23.16	How do you deal with 'lost to follow up' cases when reporting this stage of the continuum of care?	Exclude from data
		Partially exclude
		Include
23.16.1		Other (please specify)
23.17	Prisoners living with HIV who are receiving ART	
23.17.1	Prisoners living with HIV who are initiating ART	
23.17.2	Prisoners reinitiating antiretroviral treatment (among those initiating antiretroviral treatment)	
	<b>Stage 4: What is the number of prisoners living with HIV who had VL ≤200 copies/ml at their last visit?</b>	
23.18	Data measurement tool / source	Cohort data
		Surveillance data
		Other data source
23.18.1	Other measurement tool / source	
23.19	End date of the reporting period	
23.2	<b>Were you able to exclude the following?</b>	
23.20.1	Deaths	Yes
		No
		Partially
		Don't know
23.20.2	Out-migration	Yes
		No
		Partially
		Don't know
Q23.20.3	<b>Previous positives (people who have been previously diagnosed with HIV prior to arrival to your country)</b>	
		<b>Yes</b>
		<b>No</b>
		<b>Partially</b>
		<b>Don't know</b>
23.21	How do you deal with 'lost to follow up' cases when reporting this stage of the continuum of care?	Exclude from data
		Partially exclude
		Include
23.21.1		Other (please specify)
23.22	Prisoners living with HIV on antiretroviral treatment who have suppressed viral load	
23.22.1	Prisoners receiving a routine viral load test among those on antiretroviral treatment	
23.22.2	Prisoners who are virally suppressed among those routinely tested for viral load	
	<b>Calculated HIV testing and treatment cascade and 95-95-95 percentages</b>	<b>NO RESPONSE REQUIRED</b>
V1_prisoners	Percentage (%): Prisoners living with HIV who know their HIV status (First 95)	#DIV/0!
23.23	Is this percentage correct?	Yes
		No
23.23.1	Please manually input correct percentage:	
V6_prisoners	Percentage (%): Prisoners living with HIV who are on treatment (Target: 91%)	#DIV/0!
23.24	Is this percentage correct?	Yes
		No
23.24.1	Please manually input correct percentage:	
V11_prisoners	Percentage (%): Prisoners living with HIV who have a suppressed viral load (Target: 86%)*	#DIV/0!
23.25	Is this percentage correct?	Yes

		No
23.25.1	Please manually input correct percentage:	
V16_prisoners	Percentage (%): Prisoners who are on treatment among those who know their HIV status (Second 95)	#DIV/0!
23.26	Is this percentage correct?	Yes
		No
23.26.1	Please manually input correct percentage:	
V21_prisoners	Percentage (%): Prisoners on antiretroviral treatment who have a suppressed viral load (Third 95)*	#DIV/0!
23.27	Is this percentage correct?	Yes
		No
23.27.1	Please manually input correct percentage:	
v_unknown_prisoners	Percentage (%): Prisoners on antiretroviral treatment who have had a viral load test	#DIV/0!
23.28	Is this percentage correct?	Yes
		No
23.28.1	Please manually input correct percentage:	